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ABSTRACT 
 Mechanistic mathematical models of biological systems have been used to describe 
biological phenomena, including human disease, in the hope that one day these models 
may be used to better understand diseases, as well as to develop and optimize therapeutic 
strategies. Evolutionary algorithms, such as genetic programming, may be used to 
symbolically regress mathematical models describing chemical and biochemical species 
for which kinetic data are available. However, current evolutionary algorithms are 
restricted to the formulation of simple or approximate models due to the computational 
cost of evolving mechanistic models for more complex systems.  
 It was hypothesized that chemical reaction kinetic theory could be used to 
sufficiently reduce the model search space for an evolutionary algorithm such that it 
would be possible to infer mechanistic mathematical models of complex biological 
interactions. An evolutionary algorithm capable of formulating mass action kinetic 
models of biological systems from time series data sets was developed for a system of n-
species using heuristics from chemical reaction kinetic theory and a gene expression 
programming (GEP) based approach.   
Jason Robert White – University of Connecticut, 2014 
 
The resulting algorithm was then successfully validated on a general model of viral 
dynamics that accounted for six pathways relating the change in viral template, viral 
genome, and viral structural protein concentrations over time.  
 The algorithm was applied to generate cohort-specific models of HIV dynamics 
from a clinical data set. HIV-1 infection models were defined as sets of two ordinary 
differential equations describing the change in CD4+ T-cell and HIV-1 concentrations 
over time. The evolved models were used to generate hypotheses regarding treatment 
effectiveness and the potential for viral rebound in three cohorts of HIV-1 positive 
individuals receiving different Highly Active Antiretroviral Therapy (HAART) regimens. 
It was hypothesized by the algorithm that HAART was effective in stopping HIV-1 
propagation in two of the three cohorts studied. In the other cohort, it was hypothesized 
that HIV-1 continued to propagate and that there was the potential for viral rebound. 
 The result of this work was the development of an algorithm that can be used for 
the generation of complex mechanistic biological models based upon kinetic data with 
potential uses in fields ranging from biomedical to biotechnological. 
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CHAPTER 1 
INTRODUCTION 
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1.1. Motivation 
 Mathematical models are used in nearly all industries to analyze data, make 
predictions, and to propose improvements based upon those predictions. Most models 
describing data sets are defined by optimizing parameters taken from pre-existing model 
structures. Genetic programming allows one to carry out a symbolic regression to 
simultaneously fit both the equation structure and the parameters to a data set requiring 
only an input of the model variables and a set of available mathematical functions {+, -, 
*, /, etc} (Holland 1975, Koza 1992). Thus far, model generation by genetic 
programming has been restricted to the evolution of simple models due to challenges in 
navigating the size of the search space for complex systems of equations. 
 Recently, work has been done on model generation from experimental data sets 
without assuming any prior knowledge about system mechanism. Schmidt et al.’s Eureqa 
formulize, a symbolic regression package that uses a genetic programming approach, 
quickly fits models to input data (Schmidt and Lipson 2009). Although these models 
provide a good fit to experimental data, they often do not provide mechanistic 
information as to how species in a biological system interact. Chattopadhyay et al. 
developed an algorithm for inferring stochastic reaction mechanism from experimental 
data (Chattopadhyay et al. 2013). This algorithm was successful at generating correct 
mechanistic models on the algorithm’s error-complexity Pareto front, but some 
knowledge of the system was required in order to select the correct model from a set of 
potential models. A study by Bazil et al. provided a method for the reverse engineering of 
biological networks by generating systems of ordinary differential equations from 
experimental data (Bazil et al. 2011).  This algorithm was successful in identifying 
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candidate pathways that were known to exist but also generated many false positive 
pathways, as the algorithm was designed to minimize the number of false negative 
pathways identified.  
 A common method used in these approaches is that of genetic programming.  
Genetic programming is a type of evolutionary algorithm that generates programs or 
models of varying size and structure while not assuming any pre-defined model structure. 
The model is chosen by defining a set of functions (i.e. +, -, *, /), and a set of terminals 
(i.e. variables, real numbers) as building blocks from which to construct equations (Koza 
1992). Genetic programming works by generating a population of potential models of a 
problem where each solution consists of the defined functions and terminals. The 
potential models are ranked or scored based upon a defined fitness function. Models are 
then selected, usually in proportion to their fitness score, to undergo recombination with 
other models as well as for mutation. New models are incorporated with selected existing 
models and the new population of models is carried on to the next iteration where the 
algorithm repeats itself. A few examples where genetic programming has been used to 
create models addressing many different problems include the evolution of natural laws 
(Iba 2008, Schmidt and Lipson 2009), computer vulnerability testing (Kayacik et al. 
2011), prediction of longitudinal dispersion coefficients in streams (Azamathulla and 
Ghani 2011), protein binding sites (Bains et al. 2004), interpretation of microbial flow 
cytometric data (Davey and Davey 2011), embedding and decoding of digital watermarks 
(Usman et al. 2011), synthesis of polymorphic combinational circuits (Gajda and 
Sekanina 2011), pipe break prediction modeling (Xu et al. 2011), estimation of daily pan 
evaporation (Shiri and Kisi 2011), software engineering predictive modeling (Afzal and 
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Torkar 2011), modular neural network programming (Tsai and Lin 2011), self-
reproducing machines (Zykov et al. 2005), and steel beam load capacity prediction 
models (Gandomi et al. 2011). 
 A desirable enhancement to the genetic programming approach would lead to an 
extension of its use to the efficient generation of more complex mathematical models. 
These models, such as multi-variate systems of ordinary differential equations, would 
expand the use of this approach to model multi-variate data sets as are commonly found 
in biological systems. Gene expression programming (GEP) has been proposed as an 
enhancement to genetic programming (Ferreira 2006). In a GEP-type approach, solutions 
are encoded as a linear sequence of functions and terminals during the selection, 
recombination, and mutation operations. The encoded solutions are then mapped to 
equations for simulation and scoring.  
 Mathematical modeling of viral systems such as HIV-1, hepatitis B, and others 
has been of great interest in the hopes of developing treatment strategies based upon 
those models (de Sousa and Cunha 2010, Guedj and Neumann 2010, Krishnan 2011, 
Srivastava et al. 2002). Many models of various sizes and structures have been proposed 
for these systems taking into account a wide range of biochemical species. Depending on 
the species taken into account and their predicted relationships, the model behavior can 
vary in response to perturbation. The most comprehensive approach to determine optimal 
models describing such biochemical systems would be to assume no prior knowledge 
about the systems and the way that the species interact. A symbolic regression approach 
such as a GEP-based evolutionary algorithm could then be utilized to derive the 
mechanistic model describing the species, taking into account all necessary species 
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interactions including some that may not be inherently obvious.  The resulting model 
could then be used to make predictions about the system as well as to test and optimize 
potential therapeutics.  
Human immunodeficiency virus type 1 (HIV-1) is an important disease that has 
received significant interest from the modeling community (Aviran et al. 2010, 
Bonhoeffer et al. 1997(a,b), Burg et al. 2009, Herz et al. 1996, Nowak et al. 2000, 
Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer 2000, 
von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang 2010). In recent years, HIV-
1 treatments have significantly reduced AIDS-related mortalities and have enhanced 
long-term disease control (Dybul et al. 2001, Fagard et al.  2003, Powderly 2002, Ruiz et 
al. 2001).  These benefits have been realized in large part via use of highly active 
antiretroviral therapy (HAART) in clinical practice.  The HAART strategy consists of 
treating the disease with a combination of antiretroviral drugs.  Despite advances in 
efficacy over prior generation treatments, HAART is associated with risk of serious side 
effects that include cardiovascular disease (Domingos et al. 2009), nephrotoxic effects 
(Izzedine et al. 2009), and oral toxicities (Nittayananta et al. 2010). Up to 16% of 
patients require modification or discontinuation of their HAART regimen due to drug-
related toxicities (El-Sadr et al. 2006). 
  	  
1.2 Specific Aims 
 I hypothesize that using reaction kinetic theory to constrain model space, it is 
possible to infer mechanistic mathematical models of complex biological interactions by 
	   6	  
using an evolutionary algorithm to carry out symbolic regression. To test this hypothesis, 
the following specific aims were pursued: 
1. The development of a GEP-based evolutionary algorithm that optimized reaction 
kinetic models of biological systems from time series data sets. 
2. The generation of cohort-specific reaction kinetic models of Human 
Immunodeficiency Virus (HIV) infection from a clinical data set. 
To address these specific aims, the current symbolic regression methodology termed 
genetic programming was enhanced using a GEP-based approach to evolve more 
complex mechanistic reaction kinetic models describing multi-variate data sets. Also, 
experience in modeling HIV infection and simulating treatment outcomes was used to 
identify a clinical data set on which the GEP-based evolutionary algorithm was applied. 
 Completion of aims 1 and 2 resulted in an algorithm that could efficiently 
determine a model structure and parameters to a moderately sized time series data set. 
The algorithm required no prior knowledge of the relationship among measured 
variables. The enhancements to the genetic programming approach also allowed for the 
generation of models containing many variables. Interactions between large numbers of 
variables are commonly found in biological systems. The algorithm therefore will be 
beneficial in generation models of complex biological systems. Models describing 
biological systems have the potential to guide the discovery of drug targets and 
therapeutic strategies.  This technology also has the potential to be useful in personalized 
medicine applications. The tailoring of mathematical models to an individual’s disease 
state based upon their unique biochemical kinetic markers would allow clinicians to make 
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predictions about an individual’s disease state and to optimize treatment to the individual 
patient. 
 
1.3. Outline 
 In Chapter 2, it is demonstrated how mathematical modeling can be used to 
simulate the progression of a disease. A mass action kinetic model was used to describe 
nine biochemical species involved in the pathogenesis of oral cavity mucositis. The 
parameters of the model were optimized to a heterogeneous data set based on the shared 
pathway assumption.  
 In Chapter 3, the topic of evolutionary algorithms is introduced as the 
performance of the genetic algorithm operation termed “selection” was evaluated. It was 
found that a novel selection strategy, termed elite-variant selection, greatly improved the 
performance of the genetic algorithm in a variety of application tests. One of these tests 
included the optimization of a theoretical Highly Active Antiretroviral Therapy 
(HAART) regimen to an in silico HIV-positive subject. 
 In Chapter 4, a systems biology analysis is applied to clinical HAART regimens, 
termed Standard Treatment Interruption (STI) regimens, which were utilized to 
potentially treat a subject’s HIV while also administering less HAART. Clinically, these 
STI regimens were found to be unsuccessful compared to standard HAART and the 
systems biology approach was able to predict this without exposing subjects to a clinical 
trial. Further, using a systems biology approach it was shown that an optimal HAART 
regimen could be found that would control a subject’s HIV while also minimizing 
HAART dose and thereby reducing the risk of serious side effects. 
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 In Chapter 5, an evolutionary algorithm is described that evolves reaction kinetic 
models of biochemical systems from time series data sets. This was accomplished by 
enhancing the genetic programming methodology by using a GEP-based approach where 
reaction kinetic knowledge is leveraged and potential models are considered and 
optimized. This algorithm, significantly, assumes no prior knowledge of how 
biochemical species that play key roles in disease pathogenesis interact and it allows for 
the discovery of pathways that may exist between these species. 
 In Chapter 6, the GEP-based evolutionary algorithm was used to evolve cohort-
specific reaction kinetic models describing clinical data taken from HIV-positive 
subjects. These models described important pathways that were active in the different 
cohorts and were able to give insight as to the effectiveness of HAART regimens in 
controlling the propagation of HIV in these cohorts. 
 This work is concluded in Chapter 7 and Chapter 9 contains the Appendices. In 
Appendix 1, Common Lisp code of the elite-variant selection strategy is provided to 
complement Chapter 3. In Appendix 2, Common Lisp code that generates in silico HIV-
positive populations and simulates HAART on these populations is provided to 
complement Chapter 4. In Appendix 3, the GEP-based evolutionary algorithm and 
associated packages are provided as Mathematica code. This code complements Chapter 
5 and was applied to HIV-positive cohort data in Chapter 6.  	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CHAPTER 2 
MODELING OF ORAL CAVITY MUCOSITIS 
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2.1 Introduction 
 One example of the utility of using mathematical models to describe biological 
phenomena is the optimization and analysis of a network describing oral cavity 
mucositis. The work presented in this Chapter is my contribution of the work published 
in the proceedings of the American Society of Clinical Oncology (Peterson et al. 2008, 
Srivastava and White et al. 2011). Oral cavity mucositis is a condition observed in cancer 
patients receiving radiation therapy or chemotherapy. It is characterized by inflammation 
followed by sepsis and bacterial infection in the oral cavity (Knox et al. 2000, Niscola et 
al. 2007, Peterson 1999, Sonis 2004). The result of this condition is significant pain, 
interruption of therapy, increased costs due to hospitalization, and in some cases death 
(Lalla et al. 2008, Peterson et al. 2007).  Figure 2.1 depicts changes in the oral mucosa 
during as a result of this disease. 
 
 
Figure 2.1. Oral Mucosal Biopsies In Autologous Stem Cell Transplant Patients (Peterson et 
al. 2008). The histopathologic specimens shown here were directly obtained via oral mucosal 
biopsy specimens in autologous stem cell transplant patients prior, during and following 
resolution of acute mucositis caused by a high-dose conditioning regimen. The specimens 
illustrate tissue-based changes that are relevant to oral mucositis data. 
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Recent basic research advances have strategically contributed to (i) defining 
pathobiology of alimentary tract mucosal injury secondary to cancer therapy and (ii) 
linking molecular mechanisms with clinically important outcomes. Use of analytic 
technologies to integrate biological, clinical and computational domains represents an 
important new direction in the field, such that gaps in existing knowledge can be 
translated into novel hypotheses as well as prediction of experimental outcomes. The 
prototype presented in this study provides the basis for development of a detailed 
mathematical model for quantifying relevant components of the mucositis pathway.  
Oral and gastrointestinal mucositis can be a major toxicity secondary to high-dose 
cancer therapies, including chemotherapy and radiation administered as single agent or 
combined treatment (Peterson and Sonis 2001). Potential clinical and mechanistic 
relationships between selected targeted cancer therapies and mucosal injury have recently 
been reported as well (Keefe and Gibson 2007). Nearly all patients receiving radiation 
therapy for head and neck cancer develop clinically significant oral mucositis, with 16% 
requiring hospitalization because of its severity (Lalla et al. 2008). Severe oral mucositis 
results in unplanned radiation therapy treatment interruptions in 11% of patients. Patients 
undergoing multi-cycle chemotherapy for solid tumors are also at risk. For example, 303 
of 599 patients (51%) receiving chemotherapy for solid tumors or lymphoma developed 
at least World Health Organization Grade 3 oral and/or gastrointestinal mucositis. 
Reduction in subsequent dose of chemotherapy was twice as common after cycles with 
mucositis than after cycles without mucositis, thus creating the potential for less than 
optimal tumor response. 
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Current work is fostering development of novel, molecularly targeted 
interventions to reduce severity and duration of oral mucositis in selected cancer patient 
cohorts (Peterson et al. 2007). Important principles of the current pathobiologic model of 
mucositis include the role of pro-inflammatory cytokines (Sonis 2007), tissue-based 
genetic risk and resistance mechanisms (Belinsky et al. 2007, Boerma et al. 2007, Duan 
et al. 2007) and symptom clusters (Aprile et al. 2008, Campagnaro et al. 2008). 
However, key gaps in knowledge remain across the molecular, tissue and clinical 
continuum relative to strategically advancing this multidimensional modeling. In this 
study, it was shown that Virtual Cell (http://vcell.org) (Schaff et al. 1997, Slepchenko et 
al. 2003) represents a unique technology to address these complex research issues. Effort 
was directed to development of a new computational strategy to bridge “top down”, 
clinically-based events with complex, “bottom up” molecular pathways. It was 
demonstrated that using computational modeling fosters integration of data from recent 
studies (Jain et al. 2006, Knorr and Srivastava 2005, Moraru and Loew 2003, Schaff et 
al. 1997, Slepchenko et al. 2003) that have characterized pathways associated with up-
regulation of pro-inflammatory molecules including NF-κB, COX-2 and IL-6. The goal 
of this research was to provide new molecular insights into both causation of alimentary 
tract mucosal injury in cancer patients as well as the relationship of associated pathways 
to clinical consequence with the hope of forming novel hypotheses on how to down-
regulate this condition. 
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2.2 Methods 
 Integration of available data into a coherent model is an important approach to 
precisely defining the collective molecular complexities of mucositis. Determination of 
the physiological characteristics that the model is able to capture is designed to elucidate 
specific components and mechanisms. The current paradigm capitalizes on prior studies 
in order to generate this new line of research (Jain et al. 2006, Knorr and Srivastava 
2005, Moraru and Loew 2003, Schaff et al. 1997, Slepchenko et al. 2003). The current 
view of mucositis pathogenesis includes the theory of multiple shared pathways across 
the continuum of alimentary tract mucosa (Sonis 2007). A “systems biology” approach, 
in which data collected from these shared pathways are leveraged and integrated into a 
comprehensive computational model of mucositis, can potentially define commonalities 
and differences among causation of the collective mucosal injury. Using these shared 
pathways as a foundation, it is possible to apply the theory of reaction kinetics to develop 
a mathematical model of the interactions among what are believed to be key components 
involved in mucositis. The current model that I assembled accounts for interaction 
dynamics among COX-1, COX-2, TNF-α, PGE-2, IL-1β, IL-6, PGI-2, TXA-2 and NF-
κB, and includes the effect of biological feedback loops among all the species (Peterson 
et al. 2008). The model is described by Equations 2.1-2.9 and is depicted as a network 
structure in Figure 2.2. 
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𝑑 𝑁𝐹 − 𝜅𝐵𝑑𝑡 = 𝑘! + 𝑘! 𝑇𝑁𝐹 − 𝛼 + 𝑘! 𝐼𝐿 − 1𝛽 + 𝑘! 𝑃𝐺𝐸 − 2  −𝑘![𝑁𝐹 − 𝜅𝐵] (2.1) 𝑑[𝑇𝑁𝐹 − 𝛼]𝑑𝑡 = 𝑘! + 𝑘! 𝑁𝐹 − 𝜅𝐵 − 𝑘![𝑇𝑁𝐹 − 𝛼] (2.2) 𝑑[𝐼𝐿 − 1𝛽]𝑑𝑡 = 𝑘! + 𝑘!" 𝑁𝐹 − 𝜅𝐵 − 𝑘![𝐼𝐿 − 1𝛽] (2.3) 𝑑[𝐶𝑂𝑋 − 2]𝑑𝑡 = 𝑘!" − 𝑘!"[𝐶𝑂𝑋 − 2] (2.4) 𝑑[𝐶𝑂𝑋 − 1]𝑑𝑡 = 𝑘!" − 𝑘!"[𝐶𝑂𝑋 − 1] (2.5) 𝑑[𝑃𝐺𝐸 − 2]𝑑𝑡 = 𝑘!" 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!"[𝑃𝐺𝐸 − 2] (2.6) 𝑑[𝑃𝐺𝐼 − 2]𝑑𝑡 = 𝑘!" 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!"[𝑃𝐺𝐼 − 2] (2.7) 𝑑[𝑇𝑋𝐴 − 2]𝑑𝑡 = 𝑘!! 𝐶𝑂𝑋 − 2 + 𝑘!" 𝐶𝑂𝑋 − 1 − 𝑘!"[𝑇𝑋𝐴 − 2] (2.8) 𝑑[𝐼𝐿 − 6]𝑑𝑡 = 𝑘!" + 𝑘!" 𝑁𝐹 − 𝜅𝐵 − 𝑘!"[𝐼𝐿 − 6] (2.9) 
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Figure 2.2. Oral Mucositis Network Schematic (Peterson et al. 2008). Oral mucositis is 
initiated by chemotherapy or radiation therapy. The transcription factor NF-κB is activated 
directly by these therapies or through the production of reactive oxidative species. NF-κB up-
regulates many genes including the cytokines IL-6, IL-1β, and TNF-α. The enzymes COX-1 and 
COX-2 are also up-regulated which in turn catalyze the production of the PGE-2, PGI-2, and 
TXA-2 cytokines. PGE-2, IL-1β, and TNF-α can feedback to activate additional NF-κB. The “*” 
represents constitutive processes and red bars denote degradation reactions.  
 
To conduct the computational simulation, it was necessary to associate a 
parameter with each reaction. Estimation of parameter values was conducted using the 
Virtual Cell software platform (Schaff et al. 1997, Slepchenko et al. 2003), based on a 
combination of data in the literature and primary experimental data. Ideally, the collective 
kinetic data should be based on a single cohort of human studies of oral mucositis. 
However, the relatively limited scope of published data often dictates that heterogeneous 
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data sources be used. These sources may include data from different human studies, or 
from studies using animal models such as murine or rat. A literature survey, conducted to 
delineate necessary data to estimate the parameters, determined that the quantity of 
kinetic data for many of the oral mucositis reactions was sparse to non-existent, even 
when evaluating heterogeneous data sources. For example, no data on PGE-2 kinetics for 
oral mucositis was found in any animal model or human studies. Based on the shared 
pathway assumption, PGE-2 kinetic data from murine inflammatory bowel disease (IBD) 
modeling was ultimately utilized (Melgar et al. 2006). 
 
2.3 Results 
 Reaction parameters for the oral mucositis model were estimated using Virtual 
Cell and are reported in Table 2.1. Once parameters for the model based on data from 
oral mucositis and IBD were estimated, it was possible to carry out simulations of the 
mucositis process. The timeframe examined was divided into two components. The first 
15 days post-chemotherapy involved the “injury and wounding phase” of tissue toxicity. 
The remaining 85 days were identified as the “healing phase.” It was experimentally 
observed that seven of the nine species reached a plateau in species concentration over 
the observed 100-day timeframe (Peterson et al. 2008). The only species not to reach a 
plateau during the healing phase were TXA-2 and PGI-2. The model was capable of 
predicting the difference between the initial and plateau values of the seven remaining 
species within experimental error. 
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Table 2.1. Oral Mucositis Model Parameters 
k?? 12.49 uM NF-κB/day 
 
k?? 100.97 mRNA/GAPDH/(day*uM 
NF-κB) 
k?? 51.63 pg/ml/(day*ng mRNA) 
k? 10.10 uM NF-κB/(day*mRNA) 
 
k?? 90.67 1/day k?? 448.04 pg/ml/(day*ng mRNA) 
k? 12.21 uM NF-κB/(day*mRNA) 
 
k?? 119.97 ng RNA/(day*uM NF-κB) k?? 0.02 1/day 
k? 2.71*10
-6 uM NF-κB/(day*pg/100 
mg tissue) 
k?? 2.71 1/day k?? 55.59 pg/ml/(day*ng mRNA) 
k? 53.17 1/day 
 
k?? 1738.18 ng mRNA/day k?? 3675.93 pg/ml/(day*ng mRNA) 
k? 463.67 mRNA/GAPDH/day 
 
k?? 6.12*10
-18 1/day k?? 0.03 1/day 
k? 5.28*10
-19 
mRNA/GAPDH/(day*uM NF- κB) 
k?? 8.88*10
-19 pg/100 mg 
tissue/(day*ng mRNA) 
k?? 36.36 mRNA/GAPDH/day 
k? 1269.85 1/day 
 
k?? 40.54 pg/100 mg tissue/(day*ng 
mRNA) 
k?? 56.80 mRNA/GAPDH/(day*uM 
NF- κB) 
k? 105.16 mRNA/GAPDH/day 
 
k?? 0.04 1/day k?? 351.37 1/day 
 
Results for five of the seven species are shown in Figure 2.3, with the remaining 
two species not shown due to the differences in scale. In studying the dynamics during 
the injury and wounding phase of the molecular species involved in mucositis, the model 
was able to reproduce the dynamics of TXA-2 and PGI- 2, which were the only species 
not to reach a plateau (Peterson et al. 2008). The model was unable to reproduce the 
dynamics observed in this phase for the other species. The inability to reproduce these 
dynamics may be due to a number of reasons: (i) the interactions among the components 
may be incomplete or erroneous; (ii) the differences among kinetics of the shared 
pathways may be sufficiently significant to make the shared pathway assumption a poor 
one in this case; or (iii) variation among different data sources (human, mouse, and rat) 
may be result in substantial, detrimental impact estimation of reaction parameters. This 
work therefore highlights the importance of conducting appropriately designed 
experiments from a single cohort of test subjects. In doing so, it will be possible to 
remove inaccuracies associated with the last two confounders cited above, namely, the 
shared pathway assumption and the use of heterogeneous datasets. 
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Figure 2.3. Results of Oral Mucositis Model Simulations (Peterson et al. 2008). The 
difference between initial species level and final plateau levels are illustrated for the Virtual Cell 
simulation versus experimental data and data from the literature (Lipniacki et al. 2004, Sun et al. 
2001). The units for NF-κB are µm, for COX-2 are ng of mRNA, and for IL-1β, IL-6 and TNF-α 
are mRNA levels normalized for GAPDH. Note that the NF-κB data derive from an independent 
simulation (Lipniacki et al. 2004); they thus do not have an associated experimental error. This 
analytic strategy with NF-κB illustrates the ability of the modeling to integrate data from diverse 
sources.  
 
2.4 Discussion 
Mucositis can be a significant dose-limiting complication of cancer therapy. 
Higher-dose cancer treatment regimens might become feasible if the toxicity could be 
prevented or substantially reduced in severity. More aggressive cancer therapies could in 
turn produce higher cancer cure rates and/or more durable remissions. There are a 
number of potential benefits to utilizing a systems biology approach to enhance the 
modeling of mucositis. The simulations completed to date have been important in two 
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respects. First, they have highlighted key gaps in the literature that need to be addressed. 
Second, a number of key experiments have been suggested, along with how those 
experiments should be designed. An example of implementing these two outcomes is 
directed to detailed analysis of interactions among species during the injury and 
wounding phase, particularly at the very early stages. To this end, an important specific 
experiment would involve study of kinetic data for PGE-2 dynamics. Furthermore, a 
homogeneous dataset needs to be collected from a single cohort for the molecular species 
in question. Ideally, a human cohort should be utilized. However, studies from animal 
models could also prove to be highly beneficial if integrated into a single, comprehensive 
experiment. As the model matures, it will permit study of additional key avenues of 
research including studying the mechanisms by which selected oral mucosal sites (e.g., 
hard palate) are relatively resistant to high-dose cancer therapy, while other sites are 
highly susceptible to injury (e.g., buccal mucosa, soft palate) and selected non-oral 
mucosal sites (e.g., conjunctival mucosa) are rarely clinically affected by high-dose 
chemotherapy, while other sites (e.g., selected oral mucosal sites) are highly susceptible. 
 Future applications could also include the study of pharmacologic interventions 
that enhance tumor susceptibility to cancer therapy as well as reducing mucosal injury. 
This technology represents an innovative strategy to accelerate future laboratory and 
clinical investigations directed to network pathways and cancer treatment research. The 
model-based analysis has potential for utilization for personalized medicine. By 
determining the specific parameters of an individual, the technology could evaluate 
customized mucositis management strategies for that patient, with resultant reduction in 
cancer treatment toxicity. 
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CHAPTER 3 
DEVELOPMENT OF AN ELITE-VARIANT SELECTION STRATEGY FOR 
GENETIC ALGORITHM OPTIMIZATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
	   21	  
3.1 Introduction 
The work presented in this Chapter is my contribution towards an oral 
presentation given by me at the Biomedical Engineering Societies Annual Meeting in 
2011 (White and Srivastava 2011). Significantly, I demonstrate how an improvement to 
the genetic algorithm selection operation results in rapid convergence of the algorithm in 
many cases. Because genetic algorithm approaches are often computationally intensive, 
this approach has the benefit of greatly reducing the time needed to converge upon a 
desired solution. 
Genetic algorithms are a subset of evolutionary algorithms used to optimize 
solutions to complex problems by means of evolving a solution most fit to solve a given 
problem from a pool of possible solutions (Arnold and Beyer 2006, Bäck 1996, Fang et 
al. 2010, Goldberg 1989, Holland 1975, Iba 2008, Schwefel 1993, Tang and Wu 2009). 
During the course of this evolution, possible solutions, referred to as chromosomes, are 
selected to undergo recombination and mutation so that better solutions may be 
discovered while also maintaining diversity in the population of solutions. This diversity 
in the population of solutions allows for a broad search of the solution space so that the 
population will not prematurely converge to a local optimum. The cycle of selection, 
recombination, and mutation either repeats itself for a set number of iterations, also 
known as generations, or until a specified termination criterion has been reached. 
Although extensive research on different approaches for carrying out selection, 
recombination, and mutation in evolutionary algorithms has been carried out (De Jong 
and William 1991, Deb et al. 2002, Eremeev 2008, Gallagher and Frean 2005, Gero and 
Kazakov 2001, Jansen et al. 2005, Nomura and Shimohara 2001, Rowe et al. 2004, 
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Whitley 1989), this work will focus primarily on selection.  
Common examples of selection methods include Tournament selection, 
Proportional selection, Linear Ranking selection, and Elite selection. The Tournament 
selection approach involves selecting the chromosome which is the best fit of a randomly 
populated sub-population of specified size to take part in recombination and mutation 
with another chromosome selected in the same manner (Blickle and Lothar 1995). By 
doing this, Tournament selection balances convergence of the population to an optimum 
with maintaining population diversity so that the population does not become uniform at 
a local optimum thereby giving it a chance to arrive at the global optimum. Likewise, 
Proportional selection maintains this balance by assigning a weight to each chromosome 
proportional to its fitness score (Schwefel 1993). In this way, selecting a chromosome to 
take part in recombination and mutation can be related to spinning a roulette wheel where 
the slot size is proportional to the fitness of the chromosome with the most fit having the 
largest slot and the least fit having the smallest slot. Like Tournament selection, the fittest 
chromosome in a population is not guaranteed to enter into recombination or be carried to 
the next generation, but has the greatest likelihood of doing so.  
Linear Ranking selection attempts to overcome the bias that may enter 
Tournament or Proportional selection when a “super chromosome”, or a chromosome 
that is significantly fitter than other chromosomes, enters the population by weighting 
chromosomes in the population relative to fitness rank rather than fitness score (Baker 
1985). A linear relationship between rank and likelihood of being selected is then 
established so that the top ranked chromosome will be the most likely to be selected, and 
the last ranked chromosome will be the least likely to be selected. Addressing this bias in 
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Proportional and Tournament selection may avoid a situation where a “super 
chromosome” is continuously selected for recombination, leading to a homogenized 
population that plateaus at a local optimum resulting in an undesirable solution.  
Finally, Elite selection is a method that balances convergence with population 
diversity by copying an “elite” fraction of chromosomes untouched to the next 
generation, thereby keeping better scoring genetic material for use in the next generation 
(Costa and Oliveira 2003). The remainder of the new generation is populated by 
chromosomes that are randomly selected and are either simply copied or undergo 
recombination and/or mutation based on some pre-determined probability. This selection 
method has the advantage of being able to progress towards the optimum by means of 
keeping the best genetic material in the population. Elite selection also maintains 
population diversity by selecting random chromosomes for recombination and mutation 
without regard to fitness score or rank.  
The goal of this work was to achieve an improvement in the balance between 
convergence and population diversity in genetic algorithm selection, which will 
ultimately allow desirable solutions to be reached faster. It is hypothesized that the 
selection process in genetic algorithms can be configured in such a way that convergence 
to a global optimum or termination criterion will occur in a timely fashion for a large 
scope of problems, while also broadly probing the search space in order that the 
population of solutions does not plateau at a local optimum. Such a selection method 
would offer a clear improvement over currently existing selection methods. In an effort to 
address these goals, an Elite Variant (EV) selection strategy is presented. The EV 
selection strategy has been designed to take the desirable aspects of Elite selection one 
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step further to a selection strategy that converges more rapidly than the Elite selection 
method while maintaining the ability to preserve a diverse population and a broad search 
of the solution space. 	  
3.2 Methods 
3.2.1 Development of Elite Variant Selection Genetic Algorithm 
Genetic algorithms follow a common methodology of utilizing selection, 
recombination, and mutation operators to evolve a population of possible solutions 
towards the optimal solution. The selection operator determines which possible solutions 
or chromosomes are selected to undergo recombination. The recombination operator then 
determines whether the selected chromosomes will pass to the next generation unaltered 
or recombined. If the chromosomes are to be recombined, one or more chromosome 
positions are randomly selected at which genetic material from the selected chromosomes 
will be exchanged. Finally, each position or allele in each selected chromosome is given a 
small chance to be mutated to a different value.  
Implementation of a genetic algorithm using Elite Variant (EV) selection, 
summarized in Figure 3.1, may be carried out as follows. An initial pool of a specified 
size is populated by possible solutions or chromosomes. The user specifies the nature of 
these possible solutions. The chromosomes in the population are then scored in relation to 
a defined scoring metric. Depending on the nature of the problem, one may wish to 
maximize or minimize the scores of the chromosomes to a desired global optimum or 
user-specified termination criterion. For the first iteration or generation, the algorithm 
behaves as the Elite selection strategy algorithm does, and a fixed percentage of the best 
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scoring chromosomes are copied to the next-generation population. For this study the top 
20% of the best scoring chromosomes was chosen to be copied to the next generation 
when using the Elite selection strategy, although another appropriate fraction could be 
chosen.  
The final 80% of the next generation are then composed of pairs of chromosomes, 
which are selected randomly and given a 70% probability to breed or recombine with 
each other. After this recombination step, each part of both chromosomes is given an 
opportunity to mutate. The chance of mutation is set at 5% in order to ensure a diverse 
population. Random pairs of chromosomes are selected for the recombination and 
mutation steps until the size of the next-generation population equals that of the initial 
population. My code written in Common Lisp for the EV selection strategy can be found 
in Appendix 1. 
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Figure 3.1. Genetic Algorithm Using Elite 
Variant Selection (White and Srivastava 2011). 
A genetic algorithm using Elite Variant selection 
will require input as to the desired population 
size, chromosome length, and termination 
criterion. This diagram assumes that the objective 
function is to minimize the chromosome score. 
The first generation of the EV selection algorithm 
will always use Elite selection. Starting with the 
second generation, the algorithm will check every 
generation to see if Elite Variant or Elite selection 
should be used. The output of the algorithm will 
be a scored population of chromosomes, where 
the best scoring chromosome can be considered 
the optimized solution given the scoring metric 
and termination criterion. The use of Elite Variant 
selection will facilitate “leaps” in the evolution of 
the population of chromosomes while the use of 
Elite selection will give the population a means of 
escaping a local optimum. 	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The algorithm then iterates and returns to the scoring step. The next-generation 
population becomes the current working population and is scored and sorted. At this 
point, EV selection is called. First, the score of the top-scoring chromosome in the 
current population is compared to the top-scoring chromosome of the previous 
generation. If the scores are the same, it is assumed that the top-scoring chromosome is 
currently at some local optimum. In this case, the algorithm continues to populate the 
next-generation population according to the Elite selection strategy, as in the first 
generation. If the top-scoring chromosome of the current generation is better (higher or 
lower depending on if the problem is a maximization or minimization problem), then the 
algorithm proceeds according to EV selection in an attempt to facilitate convergence 
along the current path. First, the top-scoring chromosome is copied to the next 
generation. In the case of an even population size, the first two top-scoring chromosomes 
are copied to the next generation. The rest of the next-generation population is made up 
of chromosome pairs containing one random chromosome and the best-scoring 
chromosome. These chromosome pairs are then recombined. Two random chromosome 
positions are selected at which genetic material is exchanged. Each part of the 
recombined chromosomes is also given a 5% chance to mutate.  
The algorithm once again iterates to the next generation and continues to iterate 
until a specified amount of generations have been completed or a termination criterion 
has been reached. The critical decision point in each generation is whether or not the 
best-scoring chromosome in the working generation is better scoring than the best-
scoring chromosome of the previous generation. If the scores are equal, then the next-
generation population is determined according to the Elite selection strategy, while if the 
	   28	  
score has improved, the next-generation population is determined according to the EV 
selection strategy.  
The purpose of the EV selection method is to facilitate “leaps” in the evolution of 
the population while at the same time maintaining its diversity and ability to search a 
broad range of the solution space as to not plateau at some local optimum. This is 
accomplished first by preserving genetic material that yields a good score in comparison 
to other genetic material and by also breeding that genetic material with other randomly 
selected chromosomes to possibly create even better chromosomes. Since the best-
scoring chromosome is forced to breed with other randomly selected chromosomes in EV 
selection generations, the algorithm is pushed to continually improve at a rapid rate. At 
the same time, the algorithm can maintain its diversity by reverting back to the Elite 
selection strategy when an improvement is not discovered. The mutation rate is also set to 
5%, a high rate when compared to most genetic algorithm applications, in an effort to 
maintain adequate diversity. 
 
3.2.2 Application of Test Cases to Elite-Variant Selection Genetic Algorithm 
In an effort to compare Elite Variant selection to other commonly used selection 
methods, genetic algorithms using EV, Elite, Tournament, Proportional, and Linear 
Ranking selection were applied to multiple test problems taken from the literature.  
Five test functions were used to evaluate the ability of genetic algorithms using 
each selection strategy to evolve to a global optimum (Oltean 2005). The functions used 
are listed in Table 3.1. Each algorithm in all five tests had a population size of 100 
chromosomes and a chromosome length of 100 integers. The integers comprising the 
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chromosomes were initialized randomly to values between -100 and 100 for Function 
Test 1, between -10 and 10 for Function Test 2, between -30 and 30 for Function Test 3, 
between -5 and 5 for Function Test 4, and between -500 and 500 for Function Test 5. The 
optimal solution for all five test functions was a chromosome made up entirely of 0’s 
which would yield a score of 0. The goal therefore was to minimize the chromosome 
score. Each algorithm was programmed to terminate after 25,000 generations. For each 
function test, 50 trials were conducted per selection strategy.  	  
Table 3.1: Genetic Algorithm Function Tests (Oltean 2005)	  
Function Test 1	  
  
F1 = (xi2)
i=1
n
∑ 	  
Function Test 2	  
  
F2 = xi
i=1
n
∑ + xi
i=1
n
∏ 	  
Function Test 3	  
  
F3 = (100* (xi+1 − xi2)2 + (1− xi)2)
i=1
n−1
∑ 	  
Function Test 4	  
  
F4 =10* n + (xi2 −10*cos(2*π * xi))
i=1
n
∑ 	  
Function Test 5	  
  
F5 =
1
4000 (xi
2) − (cos( xi
i
)) +1
i=1
n
∏
i=1
n
∑ 	  
	  
Next, a satisfiability problem (De Jong and William 1991, Lardeux et al. 2006) 
was tested on each selection strategy. In this case, the desired solution was a binary string 
of 0’s and 1’s specified by the user. One point was added to the score of a chromosome 
for each position that did not match the desired solution. For example, if position 29 in 
chromosome 39 contained a “1”, but position 29 of the solution contained a “0”, one 
	   30	  
point was added to the score of chromosome 39. The goal was to minimize the 
chromosome score; a score of zero would signal that the solution had been found. In this 
study, the solution was randomly generated prior to every trial and each position in the 
initial population of chromosomes was initialized between 5 and 10 so that each trial was 
initialized at a sufficiently unsatisfactory solution. The population was again set to 100 
chromosomes and the chromosome size was also set to 100 positions or alleles. It was 
again observed how quickly and how close a genetic algorithm with a specified selection 
strategy could evolve towards the optimal solution. The termination criterion was set to 
25,000 generations. For each selection strategy, 50 trials were again carried out. 
Finally, a complex problem involving the use of genetic algorithms to evolve 
Highly Active Antiretroviral Therapy (HAART) regimens for Human Immunodeficiency 
Virus (HIV) subjects was explored using EV as well as the other selection strategies 
under investigation. The problem constituted determining an optimum 200-day HAART 
dosage schedule for a theoretical subject described by a mathematical model. The model 
is given by Equations 3.1-3.5 and is schematically depicted in Figure 3.2 as a 
biomolecular reaction kinetic network (Wu and Zhang 2010). 
 𝑑[𝑇!]𝑑𝑡 = 𝑘! − 𝑘! 𝑇! − 𝑘! 1− 𝑅𝑇 𝑉! 𝑇! − 𝑘!"[𝑉!][𝑇!] (3.1) 𝑑[𝑇!]𝑑𝑡 = 𝑘! 1− 𝑅𝑇 𝑉! 𝑇! − 𝑘![𝑇!] (3.2) 𝑑[𝑇!]𝑑𝑡 = 𝑘!" 𝑉! 𝑇! − 𝑘![𝑇!] (3.3) 𝑑[𝑉!]𝑑𝑡 = 𝑘! 1− 𝑘!! 1− 𝑃𝐼 𝑇! − 𝑘![𝑉!] (3.4) 
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𝑑[𝑉!]𝑑𝑡 = 𝑘! 𝑇! + 𝑘!𝑘!! 𝑇! − 𝑘![𝑉!] (3.5) 
	  	  
	  
	  
Figure 3.2. HIV Dynamic Model (based on Wu and Zhang 2010). In the presence of HIV, 
uninfected CD4+ T-cells can be infected by drug-sensitive (black dots) or drug-resistant (red 
dots) virus resulting in infected CD4+ T-cells. These infected T-cells then proceed to produce and 
release additional virus. Mutation in the drug-sensitive HIV can also result in new drug-resistant 
HIV. Highly Active Antiretroviral Therapy (HAART), which consists of two types of reverse 
transcriptase inhibitors (teal boxes and blue parallelograms) and a protease inhibitor (blue 
triangles), inhibits the ability of HIV to reproduce in infected cells rendering the virus inactive. 
All model components are subject to degradation pathways. 	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In this model, [Tc] represents the concentration of uninfected CD4+ T-cells, [Ts] 
represents the concentration of CD4+ T-cells infected by drug-sensitive HIV, [Tr] 
represents the concentration of CD4+ T-cells infected by drug-resistant HIV, [Vs] 
represents the drug-sensitive HIV, and [Vr] represents the drug-resistant HIV. Uninfected 
CD4+ T-cells are constitutively produced (described by zero-order reaction parameter k1) 
and are subject to degradation (k2). They can also be lost due to infection by drug-
sensitive (k9) and drug-resistant (k10) HIV. Infection by drug-sensitive HIV is modulated 
by the presence of reverse transcriptase inhibitors (RT). CD4+ T-cells infected by drug-
sensitive HIV are the result of the infection of uninfected cells with drug-sensitive HIV 
and can be lost to degradation (k3). CD4+ T-cells infected by drug-resistant HIV are the 
result of the infection of uninfected cells with drug-resistant HIV and can also be lost to 
degradation (k4). Drug-sensitive HIV is produced by drug-sensitive HIV infected T-cells 
(k5) and is subject to degradation (k7). The production of new drug-sensitive HIV can be 
impeded by protease inhibitors (PI) and mutation to a drug-resistant strain (k11). Finally, 
drug-resistant HIV is produced by drug-resistant HIV infected T-cells (k6) and is also 
subject to degradation (k8). Drug-resistant HIV levels also increase when drug-sensitive 
HIV mutates to a drug-resistant strain. Both reverse transcriptase inhibitors and protease 
inhibitors are present in HAART. The model parameters are listed in Table 3.2. 	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Table 3.2. HIV Dynamic Model Parameters (Wu and Zhang 2010)	  
Parameter	   Description	   Base Value	  
k1	   Growth rate of T cells	   10 cells/(mm3*day)	  
k2	   Death rate of T cells	   0.01/day	  
k3	   Death rate of T cells infected by sensitive virus	   0.02/day	  
k4	   Death rate of T cells infected by resistant virus	   0.01/day	  
k5	   Growth rate of sensitive virus	   8/day	  
k6	   Growth rate of resistant virus	   8/day	  
k7	   Natural death rate of sensitive virus	   30/day	  
k8	   Natural death rate of resistant virus	   30/day	  
k9	   Natural death rate of T cell infection by sensitive virus	   3*10-4 mm3/(virons*day)	  
 k10	   Natural death rate of T cell infection by resistant virus	   5*10-5 mm3/(virons*day)	  
 k11	   Mutation rate of virus	   0.2	  
	  
An optimal treatment will maintain the uninfected T-cell levels above 500 
cells/mm3 and the combined HIV titer below 50 virons/mm3 while minimizing the 
amount of treatment administered. The bounds on the Tc and HIV titers are taken from 
Office of AIDS Research Advisory Council’s definition effective HIV treatment (Panel 
2009). The purpose of minimizing the total treatment dosage is to reduce the subject’s 
risk of suffering dose-associated toxicities. Genetic algorithms have been used as a tool to 
optimize HAART regimens for theoretical subject (Castiglione et al. 2007). Genetic 
algorithms were therefore programmed using each selection method under investigation 
to optimize HAART treatment for HIV in the theoretical subject. The fitness of each 
chromosome was calculated by summing the penalties incurred by both failing to keep 
the Tc levels and HIV titers outside the respective bounds and by treatment dosage. Each 
chromosome consisted of 200 daily dosages of HAART ranging between 0% and 100% 
of full HAART dosage. The objective of each algorithm was to minimize the 
chromosome score. For each selection strategy, ten trials were conducted. The algorithms 
were carried out over 2,000 generations and the treatment score results as well as the 
effect of each treatment on the HIV model variables were compared to determine which 
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algorithm provided the best treatment strategy. 
 
3.3 Results 
3.3.1 Function Tests 
Utilization of the Elite Variant (EV) selection method resulted in significantly 
faster convergence to the global optima of Function Tests 1-4 as shown in Figures 3.3a-d. 
Although convergence to the global optimum never occurred for Function Test 5 after 
25,000 generations, the use of Elite Variant selection yielded a significantly better 
scoring result, shown in Figure 3.3e.  
Function Test 1 (see Figure 3.3a) displayed convergence of the genetic algorithms 
using EV and Elite selection to the global optimum, which is a string of 0’s with a 
chromosome score of 0. Use of EV selection resulted in convergence to the global 
optimum in all 50 EV trials after 21,000 generations, with 98% of trials converging by 
generation 14,500. Using Elite selection, 94% of trials reached the global optimum after 
25,000 generations. In comparison to the EV method, 0% of Elite trials reached the 
global optimum after 14,500 generations. The Tournament, Proportional, and Linear 
Ranking selection algorithms all quickly reached local optima at chromosome scores of 
approximately 600, 1,800, and 40,000 respectively (Linear Ranking data not shown) and 
were not able to escape the local optima by generation 25,000. None of the trials using 
these selection methods resulted in the optimal solution.  	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Figure 3.3. Evolution of Solutions in Function Tests. Genetic algorithms programmed to solve 
Function Tests 1 (A), 2 (B), 3 (C), 4 (D), and 5 (E) were carried out over 25,000 generations. The 
best scoring chromosome was plotted every 50 generations for genetic algorithms using Elite-
Variant (blue), Elite (red), Tournament (green), Proportional (gold), and Linear Ranking (brown) 
selection methods. For each test, 50 trials were carried out per algorithm. It was observed that the 
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genetic algorithms using Elite Variant (EV) selection converged to better scoring solutions in less 
time than genetic algorithms using other selection methods. It was also observed that genetic 
algorithms using Tournament, Proportional, or Linear Ranking selection were not able to escape 
local optima by generation 25,000 for all Function Tests. Note: The error bars attached to the EV 
selection plot in Figure 3.3c extend beyond the graphical space and are therefore left unbounded. 
The error incurred in these trials reached values below zero and cannot be displayed on a 
logarithmic scale. 	  
Function Test 2 (see Figure 3.3b) displayed a similar result to that of Function 
Test 1 as the genetic algorithms utilizing EV and Elite selection converged to the global 
optimum, while the genetic algorithms utilizing Tournament, Proportional, and Linear 
Ranking selection quickly reached local optima at approximate chromosome scores of 
150, 350, and 550 respectively from which they were not able to escape by generation 
25,000. The Linear Ranking selection algorithm, because it placed more weight on 
chromosome rank rather than chromosome score, quickly lost the top scoring 
chromosomes from the early generations and reached an inferior local optimum as 
compared to its starting point. Genetic algorithms using EV selection reached the global 
optimum after 18,500 generations in all 50 trials. Similarly, genetic algorithms using 
Elite selection reached the global optimum after 21,500 generations in all 50 trials. A 
more telling comparison is that 90% of the EV algorithms reached the optimal solution 
after 13,000 generations whereas only 24% of the algorithms using Elite selection 
reached the global optimum at this time.  
The scale of chromosome scores in Function Test 3, as can be seen in Figure 3.3c, 
provided a challenge to each selection method. 40% of the genetic algorithm trials using 
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EV selection were able to find the global optimum after 25,000 generations. No other 
genetic algorithm trials using other selection methods were able to find the global 
optimum by generation 25,000. Likewise, EV algorithms on average yielded a 
significantly better result after 25,000 generations than did algorithms using the other 
selection methods. Recalling that lower scores are desirable in this case, the average 
results after 25,000 generations were 102.5 ± 93.0 using EV selection, 582.6 ± 251.1 
using Elite selection, 1.3*106 ± 1.9*105 using Tournament selection, 5.2*106 ± 7.0*105 
using Proportional selection, and 3.5*108 ± 6.1*107 using Linear Ranking selection.  
Function Test 4 also yielded a result similar to that of Function Tests 1 and 2, as 
can be seen in Figure 3.3d. Genetic algorithms using Tournament, Proportional, and 
Linear Ranking selection again reached local optima at approximately 580, 1,800, and 
3,900 respectively, from which they were not able to escape by generation 25,000. Again, 
the Linear Ranking selection algorithm as well as the Proportional selection algorithm by 
maintaining too broad a search of the solution space quickly lost the top scoring 
chromosomes of the early generations and reached local optimums at chromosomes 
scores greater than that of the best early generation chromosome scores. All algorithm 
trials using EV and Elite selection converged to the global optimum by generation 
25,000. In contrast, at generation 11,500, 92% of genetic algorithm trials using EV 
selection had converged to the global optimum while no trials using Elite selection had 
converged. In fact, the average chromosome score of a population in an algorithm using 
Elite selection at generation 11,550 was 10.5 ± 3.0. 
Function Test 5 displayed the most peculiar behavior of all of the Function Tests, 
as can be seen in Figure 3.3e. The results of this test showed that genetic algorithms using 
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Elite, Tournament, Proportional, and Linear Ranking selection converged along a very 
similar path while genetic algorithms using EV selection converged quickly to a more 
optimal solution. The average best solutions after 25,000 generations for algorithms using 
each selection method were 1.53 ± 0.055 for EV selection, 1.71 ± 0.067 for Elite 
selection, 1.72 ± 0.062 for Tournament selection, 1.69 ± 0.065 for Proportional selection, 
and 1.70 ± 0.061 for Linear Ranking selection. No trials were able to reach the global 
optimum in this test.  
 
3.3.2 Satisfiability Test 
Implementation of a satisfiability test, shown in Figure 3.4, also demonstrated the 
ability of the EV selection method to facilitate the convergence of a genetic algorithm to 
an optimal solution. Genetic algorithms using Tournament, Proportional, and Linear 
Ranking selection yielded results at local optimum chromosome scores of approximately 
450, 1,500, and 3,400 respectively. Again, algorithms using these selection methods were 
not able to escape these local optima by generation 25,000. Conversely, algorithms using 
EV selection converged to the global optimum by generation 16,000 in all cases with 
90% reaching this optimum by generation 12,500.  
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Figure 3.4. Evolution of Satisfiability Test Solutions. Scores of the most fit chromosomes were 
plotted every 50 generations for genetic algorithms using Elite Variant (EV) selection (blue), 
Elite selection (red), Tournament selection (green), Proportional selection (gold), and Linear 
Ranking selection (brown) to solve a satisfiability problem. The algorithm was carried out for 
25,000 generations (A), with the fastest convergence occurring in the first 4,000 generations (B). 
Each algorithm was carried out 50 times. The genetic algorithm using EV selection was able to 
solve the satisfiability problem in fewer generations than any genetic algorithm using another 
selection method. Genetic algorithms using Tournament, Proportional, or Linear Ranking 
selection were not able to solve this satisfiability problem in 25,000 generations.	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   Genetic algorithms using Elite selection also exhibited desirable convergence, 
with 96% of the trials reaching the global optimum by generation 25,000. Elite selection 
trials again did not converge as quickly as EV selection trials. In comparison, at 
generation 16,000 when all EV selection trials had converged, only 40% of the Elite 
selection trials had converged to the global optimum. 
 
3.3.3 HAART Optimization 
Genetic algorithms using the selection strategies under investigation were 
implemented to optimize Highly Active Antiretroviral Therapy (HAART) regimens for a 
theoretical Human Immunodeficiency Virus (HIV) subject. Figure 3.5 shows the fitness 
of the best scoring chromosomes plotted over 2,000 generations for each case. The 
objective once again was to minimize the chromosome score. Genetic algorithms using 
EV and Elite selection produced better scoring chromosomes in each generation as 
compared to genetic algorithms using Tournament, Proportional, and Linear Ranking 
selection. In fact, the Proportional selection and the Linear Ranking selection algorithms 
once again reached local optimums at scores above that of the best scoring early 
generation chromosomes due to too broad a search of the solution space. After 2,000 
generations, the genetic algorithm using EV selection produced an average top scoring 
chromosome score of 2,475.23 ± 18.42 while the genetic algorithm using Elite selection 
produced an average top scoring chromosome score of 2,523.34 ± 22.77. In comparison, 
the average top scoring chromosome score using EV selection was, within error, the same 
as the top scoring chromosome using Elite selection between generations 0 and 1,700. 
Even so, the EV selection algorithm maintains a clear advantage over the Elite selection 
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algorithm in regards to convergence time as the average result of the Elite selection 
algorithm after 2,000 generations was obtained by the EV selection algorithm after only 
150 generations. 
	  
Figure 3.5. Evolution of Highly Active Antiretroviral Therapy (HAART) for Treatment of 
Human Immunodeficiency Virus (White and Srivastava 2011). Genetic algorithms using EV 
(blue), Elite (orange), Tournament (red), Proportional (green), and Linear Ranking (brown) 
selection were programmed to optimize HAART over 2,000 generations for treatment of a 
theoretical case of HIV. The score of the best scoring treatment was plotted every 50 generations. 
Each algorithm was carried out 10 times. The genetic algorithm using EV selection was able to 
evolve a more optimal HAART regimen after 2,000 generations than the genetic algorithms using 
the other selection methods. In fact, the average score of the top scoring treatment as determined 
using Elite selection after 2,000 generation was equal to the average score of the top scoring 
treatment as determined using EV selection after only 150 generations. 	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Figure 3.6. Optimized Highly Active Antiretroviral Therapy (HAART) Regimens (White 
and Srivastava 2011). After 2,000 generations, the top scoring treatment was taken from each 
genetic algorithm and used to treat a theoretical case of HIV. The HAART regimen as determined 
by the genetic algorithm using EV selection (A, blue) suggested on average a daily dose of 70% 
from day 0 to day 50 followed by a decrease to a daily dose of 50% from day 50 to day 200 with 
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some fluctuation in dose. Similarly, the HAART regimen as determined by the genetic algorithm 
using Elite selection (B, red) suggested on average a daily dose of 90% from day 0 to day 50 
followed by a decrease to a daily dose of 50% from day 50 to day 200 with some fluctuation in 
dose. HAART regimens as determined by genetic algorithms using Tournament (C, green), 
Proportional (D, gold), and Linear Ranking (E, brown) selection suggest a highly variable dosage 
from day to day over the course of the 200-day treatment period. 	  
The HAART regimens evolved using genetic algorithms with different selection 
strategies are shown in Figures 3.6a-e. It was observed that HAART dosages optimized 
using Tournament, Proportional, and Linear Ranking selection fluctuated drastically each 
day. This result demonstrated the inability of the genetic algorithms using these selection 
methods to home in on an optimum HAART regimen. Conversely, HAART dosages 
optimized using EV and Elite selection were more consistent. In general, the HAART 
regimen optimized using EV selection resulted in daily dosages of 70% from day 0 to day 
50 and daily dosages of 50% from day 50 to day 200 with some variation. The HAART 
regimen optimized using Elite selection resulted in the same pattern with the exception of 
daily dosages of 90% from day 0 to day 50. The percentage of the total possible HAART 
dosage administered over 200 days was determined to be 53.28% using EV selection, 
54.70% using Elite selection, 56.08% using Tournament selection, 55.47% using 
Proportional selection, and 44.85% using Linear Ranking selection.  	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Figure 3.7. Effect of Optimized HAART on HIV Model Variables (White and Srivastava 
2011). HAART as determined by genetic algorithms using EV (blue), Elite (red), Tournament 
(green), Proportional (gold), and Linear Ranking (brown) selection was applied to the HIV model 
over a 200 days period. The effects of HAART on uninfected T-cell (A), drug-sensitive HIV 
infected T-cell (B), drug-resistant HIV infected T-cell (C), drug-sensitive HIV (D), and drug-
resistant HIV (E) levels are shown. HAART as determined using EV, Elite, and Tournament 
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selection resulted in a similar effect on all model variables with the exception of drug-sensitive 
HIV being less controlled using HAART determined using Tournament selection. HAART 
determined using Linear Ranking selection resulted in less control of the infected and a slower 
rebound of the uninfected T-cell levels. Conversely, less drug-resistant HIV and drug-resistant 
HIV infected T-cells accumulated in this case. 	  
Figures 3.7a-e show the results of each HAART regimen on the model variables. 
In Figure 3.7a, it was observed that HAART regimens produced by genetic algorithms 
using EV, Elite, and Tournament selection strategies resulted in an increase in uninfected 
T-cell (Tc) levels to the goal of 500 cells/mm3 by day 60. The HAART regimens 
produced by genetic algorithms using Proportional and Linear Ranking selection also met 
this goal, but at a later time. HAART determined by Proportional selection met the Tc 
goal around day 75 while HAART determined by Linear Ranking selection met the same 
goal around day 200. Figures 3.7b and 3.7c display a similar result for drug-sensitive (Ts) 
and drug-resistant (Tr) HIV infected T-cells for cases when HAART was determined by 
genetic algorithms using EV, Elite, Tournament, and Proportional selection. HAART 
determined by a genetic algorithm using Linear Ranking selection resulted in a higher 
concentration of drug-sensitive and a lower concentration of drug-resistant cells. 
Following these results, HIV infection was less controlled by the HAART regimen 
determined using Linear Ranking selection, as illustrated in Figures 3.7d and 3.7e. 
Indeed, Figure 3.7d showed that all HAART regimens resulted in fluctuation of drug-
sensitive virus as a result of fluctuation in treatment dosages. Because treatment dosage 
was more variable in Linear Ranking, Proportional, and Tournament selection generated 
HAART, Vs titers fluctuate to a greater extent and less control is maintained over levels 
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of drug-sensitive virus. 
 
3.4 Discussion 
The results of the Function Tests, Satisfiability Test, and HIV/HAART Test 
clearly demonstrate the advantages of using Elite Variant selection when using genetic 
algorithms to solve these problems. In all cases, algorithms using EV selection were able 
to arrive at better scoring solutions in a smaller amount of time, making it an attractive 
option when trying to quickly determine or estimate the solution of a complex problem. 
EV selection demonstrates through these tests that it is not only able to converge 
quickly to an optimum, but it is also able to completely bypass local optima that other 
selection strategies spend significant time attempting to escape. Both Elite and EV 
selection balance the broad probing of the solution space exhibited by Tournament, 
Proportional, and Linear Ranking selection with a mechanism for keeping well-
performing genetic material while effectively pursuing the objective function. EV 
selection takes this methodology one step further by forcing the population quickly to a 
local optimum while also giving the algorithm a way to escape the local optimum. The 
algorithm reverts back to the Elite selection strategy while at a local optimum and then 
switches back to EV selection upon escape facilitating “leaps” in the evolution of the 
population.  
In the examples of the Function Tests and the satisfiability test, the capabilities of 
EV selection are demonstrated. Following these results, the HIV/HAART test 
demonstrated the potential of EV selection in genetic algorithms to arrive at better 
solutions in a shorter period of time with the result being a more optimal treatment for a 
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real disease. If a particular HIV subject could be modeled by a series of differential 
equations describing the key variables at play, a genetic algorithm using EV selection 
would be able to offer a HAART regimen that would more effectively treat that subject 
according to the constraints on uninfected T-cell levels, combined HIV titers, and 
HAART dosage. In the theoretical case presented in this paper, the HAART regimen 
produced by the genetic algorithm using EV selection was able to elevate the 
concentration of uninfected T-cells as quickly as the Elite, Tournament, and Proportional 
HAART regimens. It was also able to control the combined HIV titers as well as these 
other HAART regimens. What sets the EV HAART regimen apart from these other 
treatments is that it was able to achieve these results while administering a smaller dosage 
of HAART reducing the subject’s exposure to the drug and chance of suffering dose-
associated toxicities. Conversely, the Linear Ranking HAART regimen administered a 
smaller amount of HAART than did the EV HAART regimen. In doing so, the Linear 
Ranking HAART regimen was not able to bring the uninfected T-cell levels back up to 
500 cells/mm3 nearly as fast as the EV HAART regimen was able to. It also maintained 
far less control over the level of HIV virus. Because of these behaviors, the EV HAART 
regimen was the best scoring of all the HAART regimens.  
As a result, Elite Variant selection, when used as the selection method in genetic 
algorithms, can result in better, faster solutions. It is advised, as any problem contains its 
own subtleties, that all selection methods should be tested when using a genetic algorithm 
to evolve a solution to a problem in case that particular problem is well suited to one of 
the other commonly used selection methods. A benefit of this algorithm, besides 
providing more accurate solutions to complex problems, is that the process of carrying 
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out genetic algorithms will be less computationally intensive thereby expanding a 
researcher’s capability to evolve solutions to more complex problems as well as carry out 
a greater amount of trials in a smaller amount of time. Applications of this algorithm will 
be beneficial in multiple domains in which genetic algorithms are useful, ranging from 
traditional optimization to classification technology in fields encompassing medicine, 
logistics, finance, etc.  
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CHAPTER 4 
OPTIMIZING HIV-1 TREATMENT VIA A SYSTEMS BIOLOGY APPROACH 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
 
  
	   50	  
4.1 Introduction 	   A major goal of developing mathematical models of diseases is to understand the 
underlying pathology.  One of the benefits arising from such a quantitative understanding 
is the potential to develop and optimize treatment strategies that maximize health benefits 
while minimizing secondary toxicity effects.  
 It is possible to capitalize upon recent advances in systems biology to implement 
this strategy.  By systematically perturbing the biological network underlying the disease, 
it is possible to monitor the gene, protein, and informational pathway responses; integrate 
these data; and ultimately, formulate mathematical models describing the structure of the 
system (Ideker et al. 2001, van der Greef et al. 2004).  Systems biology provides an 
impactful foundation for analysis of the comprehensive datasets that are needed in order 
to develop robust kinetic models. The technology also permits verification against 
experimental results.  Ideally, the resulting model may be used to predict progression of 
the disease (Bogojeska et al. 2010, Burg et al. 2009, Castiglione and Paci 2010, Degon et 
al. 2008, de Sousa et al. 2010, Guedj et al. 2010, Hoffmann et al. 2002, Itakura 2010, 
Perelson et al. 1996, Smith and Ribeiro 2010, Srivastava et al. 2002, von Kleist et al. 
2010, Wendelsdorf et al. 2010, Yang et al. 2007).  It is also possible to identify, develop, 
and optimize treatment strategies in a mathematically rigorous fashion.  
 HIV-1 is a key disease that has received significant interest from the modeling 
community (Aviran et al. 2010, Bonhoeffer et al. 1997(b), Nowak and May 2000, 
Perelson et al. 1996, Perelson 2002). In recent years, HIV-1 treatments have significantly 
reduced AIDS-related mortalities and have enhanced long-term disease control (Dybul et 
al. 2001, Fagard et al. 2003, Powderly 2002, Ruiz et al. 2001).  These benefits have been 
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realized in large part via use of highly active antiretroviral therapy (HAART) in clinical 
practice.  The HAART strategy consists of treating the disease with a combination of 
antiretroviral drugs.  Despite advances in efficacy over prior generation treatments, 
HAART is associated with risk of serious side effects that include cardiovascular disease 
(Domingos et al. 2009), nephrotoxic effects (Izzedine et al. 2009), and oral toxicities 
(Nittayananta et al. 2010). Up to 16% of patients require modification or discontinuation 
of their HAART regimen due to drug-related toxicities (Mocroft et al. 2005).  
 In an attempt to reduce incidence and severity of these side effects, clinical trials 
have explored various methods of reducing drug exposure by structured treatment 
interruption (STI). In STI, HAART is discontinued and resumed at pre-defined time 
intervals in an effort to control the viremia while concurrently administering the lowest 
possible dose of HAART in order to reduce toxicity (Castiglione et al. 2007, Dybul et al. 
2001, El-Sadr et al. 2006, Fagard et al. 2003, Garcia et al. 2001, Kilby et al. 2000, Ortiz 
et al. 2001, Ruiz et al. 2001).  Published STI regimens that were analyzed include 8 
weeks on – 2 weeks off (8w/2w) STI (Fagard et al. 2003) and 1 week on – 1 week off 
(1w/1w) STI (Castiglione et al. 2007, Dybul et al. 2001). These studies and their 
outcomes are listed in Table 4.1. Other STI regimens which have been studied include 1 
month on – 1 month (1m/1m) off STI (Ortiz et al. 2001) and SMART STI (El-Sadr et al. 
2006).  Unlike standard STI that discontinues and resumes treatment at pre-defined time-
points, SMART STI prescribes the initiation of treatment when the CD4+ T-cell 
concentration falls below 250,000 cells/mL and the discontinuation of treatment when the 
CD4+ T-cell concentration recovers to 350,000 cells/mL.  
	   52	  
 Despite their theoretical promise STI strategies have been largely unsuccessful. 
Thus there remains a need to define safe and effective “optimal” HAART strategies for 
large and diverse clinical cohorts. Treatment that is optimized to an individual may 
permit more effective control of that individual's HIV disease while concurrently 
reducing total HAART exposure and associated toxicities. To this end the goal of this 
study was to design an optimized dosing schema, based on an established mathematical 
model of HIV, for minimizing HAART exposure while maintaining durable virologic 
suppression.  Results were compared to clinically reported results of standard HAART 
and STI dosing regimens to further validate the conceptual framework. 
 
Table 4.1. Total HAART Dosage Prescribed By Each Treatment Regimen 
Description of Treatment 
Regimen 
HAART Administered 
 (% of maximum 
dosage) 
% of Subjects Achieving Viral 
Suppression After Treatment 
Period  
Optimized HAART 78.1% N/A 
Standard HAART 100.0% 90% 
1 week on – 1 week off STI 50.0% 80% 
8 weeks on – 2 weeks off STI 83.3% 77.5% 
 
4.2 Methods 
4.2.1 Model Selection 
 There is a substantive literature pertaining to development of models describing 
HIV-1 (Aviran et al. 2010, Bonhoeffer and Nowak 1997, Bonhoeffer et al. 1997(b), 
Bonhoeffer et al. 2000, Burg et al. 2009, Herz et al. 1996, Liang et al. 2010, Nowak et al. 
1997, Nowak and May 2000, Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009, 
Ribeiro et al. 2010, von Kleist et al. 2010, Wu et al. 2010, Wu and Zhang 2010, Zeng 
and Yang 2010). The HIV-1 dynamic model of Perelson and Nelson (Perelson and 
Nelson 1999) shown in Figure 4.1 was selected as the basis for this work because it 
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Figure 4.1. HIV Dynamic Model (based on Perelson and Nelson 1999). In the presence of 
HIV, uninfected CD4+ T-cells can be infected by HIV (black dots) resulting in infected CD4+ T-
cells. The infected T-cells then proceed to produce and release additional virions. Highly Active 
Antiretroviral Therapy (HAART), which consists of nucleoside analog and non-nucleoside 
reverse transcriptase inhibitors (teal boxes and blue parallelograms) and a protease inhibitor 
(green triangles), inhibits the ability of HIV to reproduce in infected cells rendering the virus 
inactive. All model components are subject to degradation pathways.  	  
included the action of reverse transcriptase inhibitors and protease inhibitors, both of 
which predominantly comprise HAART regimens.  The model is quantitatively described 
via a set of ordinary differential equations presented in Equations 4.1-4.3.   
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   In this model, T represents the concentration of uninfected CD4+ T-cells, TI 
represents the concentration of CD4+ T-cells infected by HIV, and V represents the HIV 
concentration. Uninfected CD4+ T-cells are constitutively produced (described by zero-
order reaction parameter k1) and are subject to degradation (k2). They can also be 
depleted due to infection by HIV (k3). Infection by HIV is modulated by the presence of 
reverse transcriptase inhibitors (RT). CD4+ T-cells infected by HIV are the result of the 
infection of uninfected cells with HIV (k3) and can be lost to degradation (k4). HIV is 
produced by HIV infected T-cells (k4, k5) and is also subject to degradation (k6). The 
production of new, drug-sensitive HIV can be impeded by protease inhibitors (PI). The 
average or baseline case parameters were derived from the literature (Perelson and 
Nelson 1999) and are listed in Table 4.2. 	  
Table 4.2. HIV Dynamic Model Parameters (Perelson and Nelson 1999) 
Parameter Description Base Value 
k1 Growth rate of T cells 10,000 cells/(mL*day) 
k2 Death rate of T cells 0.01/day 
k3 Infection of T cells by HIV 5*10-7 mL/(copies*day) 
k4 Death rate of T cells infected by virus 0.5/day 
k5 Burst size/Virions released by lysed cell 16.75 copies/cell 
k6 Natural death rate of sensitive virus 3.1/day 	  	   The Perelson and Nelson model accounted for two types of CD4+ T-cells 
(uninfected, and infected) and a general strain of HIV. These sub-populations of CD4+ T-
cells as of yet cannot be measured clinically and therefore the specific concentrations of 
these variables as reported by the model cannot be verified clinically. The predictions for 
each of these three variables made by the model were taken to be a reasonable 
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approximation of HIV infection. We anticipate the advances in technology that will allow 
for the differentiation of these subpopulations of CD4+ T-cells in the clinical setting. 
When applying HAART in this model, it was assumed that 50% of the dose 
contained a protease inhibitor and the other 50% of the dose contained a mixture of two 
reverse transcriptase inhibitors; this assumption is consistent with most HAART dosing 
recommendations (Panel 2009). In the model this was described by setting both RT and 
PI equal to 0.45, thereby quantifying the inhibition of the pathways describing HIV 
infection and propagation associated with these drugs. In this study, HAART dosages 
were reported daily on a scale that ranged from 0% (null dose) to 100% (full dose). A full 
dose (100%) in this case refers to the maximum dosage that can be administered. 
Outcomes evaluated for each dosing strategy was the range of successful treatment 
coverage (ROC), Equation 4.4, defined as the ability of the treatment to suppress the HIV 
titer below 50 copies/mL at the 48-week time point at the conclusion of the simulation. 
The 48-week time frame was chosen as it is used as a common benchmark for 
determining the efficacy of a HIV treatment regimen (Eron et al. 2006, Madruga et al. 
2007, Sanne et al. 2003). 
 𝑅𝑂𝐶 =    #!"#$%&'()*+,!!"! !"# !!!"!""#$!!"!"#$%&/!"!"#$%#!"#$%&'()*+,!!"#   (4.4) 
 
4.2.2 Optimization of Highly Active Antiretroviral Therapy (HAART) 
 A 48-week (336-day) HAART regimen was optimized for the average subject 
based on Equations 4.1 – 4.3 using the gPROMS software. gPROMS employs both 
single-shooting and multiple-shooting dynamic optimization methods to converge upon 
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an optimal solution. The average subject's biochemical indicators, described by Equations 
4.1-4.3, were allowed to equilibrate after being initiated from the initial conditions listed 
in Table 4.3. The equilibrium values for each of the 3 variables, listed in Table 4.4, were 
used as the initial conditions for HAART optimization. The optimized HAART regimen 
was described by a list of daily HAART dosages ranging from 0% to 100%.  The 
objective function, defined by Equation 4.5, was minimization of the total dosage of 
HAART. The constraint imposed was that the HIV titer remained below 50 copies/mL. 
The bound on the HIV titer was chosen based upon the detection limit and target for 
suppression of HIV RNA (Panel 2009).  
 
 
(4.5) 
	  
Table 4.3. Average Subject's Initial Conditions, Pre-Treatment 
Variable Initial Condition 
T 1,000,000 cells/mL 
TI 0 cells/mL 
V 100 copies/mL 	  
Table 4.4. Initial Conditions at the Initiation of Treatment Optimization 
Variable Initial Condition 
T 462,838 cells/mL 
TI 223,368 cells/mL 
V 557,195 copies/mL 	  
 
 
	   57	  
4.2.3 Comparison of Optimized HAART to Standard HIV-1 Treatments Administered to 
Computer-Generated Cohorts 
Seven groups of 1,000 HIV positive subject computer-generated cohorts with 
different degrees of inter-patient variation were simulated. Each computer-generated 
cohort was comprised of 1,000 computer-generated (in silico) subjects. Specifically, 
parameter values in the first group were allowed to vary randomly by as much as 4% 
from the baseline.  Parameter values in the remaining six groups were allowed to vary by 
as much 7%, 10%, 20%, 25%, 30%, or 40%. Smaller percentage parameter variation 
indicated a more homogeneous population, while higher percentage parameter variation 
indicated a cohort with a more diverse immune response. Each computer-generated 
cohort was treated with standard and STI HAART regimens, including consistent 
maximum or standard HAART dosage, an optimized HAART regimen, 8w/2w STI 
(Fagard et al. 2003), and 1w/1w STI (Castiglione et al. 2007, Dybul et al. 2001). Ten in 
silico cohorts were evaluated at each measure of inter-patient variation for each of the 
treatment regimens. Simulated treatment was initiated when the uninfected CD4+ T-cell 
count fell below 500,000 cells/mL. Standard HAART and optimized HAART were 
simulated for 48 weeks after its initiation. In order to compare results in this in silico 
study directly to past clinical trials, 8w/2w STI was simulated for 40 weeks (Fagard et al. 
2003) and 1w/1w STI was simulated for 68 weeks (Dybul et al. 2001). Subjects enrolled 
in these clinical trials had undetectable ([HIV] < 50 copies/mL) viral loads. To closely 
replicate these trials, in silico subjects were treated with full treatment until the 
concentration of HIV fell below 50 copies/mL, after which the STI was initiated. The 
same method was used to simulate the optimized HAART regimen. 
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In all simulations and if the subject's uninfected CD4+ T-cell count did not call for 
the initiation of treatment after two simulated years, the simulation of that subject was 
terminated with an output that treatment was not needed. The range of successful 
treatment coverage (ROC), defined as the ability of the treatment to suppress the HIV 
titer below 50 copies/mL by the end of the 48-week treatment cycle, was calculated for 
each test case. The results were compared to the ROC calculated for each cohort using 
the two optimized HAART regimens.  
 
4.3 Results 
4.3.1 Optimal HAART Dosage for Base Case  
 Optimization of the HAART regimen for the average subject was based upon the 
objective function, described in Methods, where total HAART dosage over the 48-week 
treatment period. The resulting predicted treatment strategy is shown in Figure 4.2.  Full 
dosage (100%) was prescribed for the first 31 days of the treatment regimen. The 
concentration of HAART prescribed then rapidly decreased, with dosages between 70% 
and 78% of full dosage prescribed between day 42 and day 324. HAART was prescribed 
at a concentration of 68.8% of full dosage for the last 10 days of the regimen. The total 
amount of HAART prescribed over the 48 weeks was 78.1% of maximum HAART 
dosage. 
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Figure 4.2. HAART Treatment Strategy Optimized for the Average Subject. Daily dosages 
of HAART are plotted over 48 weeks (336 days) as percentages of the maximum HAART 
dosage. HAART was optimized to minimize the total HAART dosage administered subject to the 
constraint that the subject’s viral load remains below 50 virons/mL. Total HAART dosage over 
the 48-week period prescribed by the optimized treatment regimen is 78.1% of the total possible 
HAART dosage. 
 
4.3.2 Comparison of HAART Strategies via Simulation Studies   
 The range of successful treatment coverage (ROC) was calculated for multiple 
simulated cohorts of subjects receiving simulated standard treatment, optimized 
treatment, 1w/1w STI, and 8w/2w STI. Successful treatment in this modeling was 
defined as the ability of the treatment to suppress the HIV titer below 50 copies/mL at the 
48-week time point. Table 4.1 lists the total amount of HAART administered by each 
treatment regimen.  
The ROC that resulted by modeling the standard HAART dosage in ten in silico 
cohorts of 1,000 in silico subjects decreased from 100% to 75.15% ± 1.68% as the 
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variation in HIV model parameters increased, as shown in Figure 4.3. When optimized 
HAART dosing was used to treat each computer-generated cohort, ROCs generally 
decreased as variation in HIV model parameters increased. 8w/2w STI ROCs decreased 
as variation in HIV model parameters increased also.  Conversely, ROCs observed for the 
1w/1w STI increased as the variation in HIV model parameters increased. 
 The different treatment regimens delineated different patterns of coverage as 
simulated inter-patient variation increased. For example, 1w/1w STI showed a pattern of 
increasing ROC with increasing variability among subjects, while conversely, optimized 
HAART, standard HAART, and 8w/2w STI showed a pattern of decreasing ROC. Also, 
the generation of “extreme cases” or computer-generated subjects with the ability to be 
strongly resistant or highly susceptible to infection was more likely to occur as inter-
patient variation was increased. As population variability increased, treatment strategies 
that provided smaller overall drug exposure, such as the 1w/1w STI, were more 
successful due to the increased number of individuals better able to deal with the disease.  
Treatment strategies that uniformly provided higher overall drug exposures, such as 
standard HAART, had lower ROCs in cohorts of greater inter-patient variability. The 
cause of the lower ROCs was because in silico subjects who were highly susceptible to 
infection were more likely to be generated, and as a result even the higher doses of 
HAART were not able to control their infection. ROCs observed for optimized HAART, 
which had the tendency to more precisely dose subjects, were found to respond much like 
standard treatment to increases in inter-patient variation. 
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Figure 4.3. HAART Range of Coverage for in silico Cohorts Using Standard and 
Customized Treatment. The range of coverage, or percentage of subjects successfully 
responding to HAART, is plotted using each treatment strategy under investigation. HAART was 
applied to in silico cohorts simulating variation among cohorts by varying the HIV dynamic 
model parameters by 4%, 7%, 10%, 20%, 25%, 30%, and 40%. Successful treatment was 
regarded as the ability of the treatment strategy to suppress a subject’s HIV titer below 50 
copies/mL after 48 weeks. 
 
4.3.3 Comparison of Simulation to Experimental STI Results 
The ROCs observed by simulating inter-patient variation at 25% variability in the 
model parameters were found to be most comparable to ROCs observed clinically, as 
shown in Figure 4.4. Significant discrepancies in clinical ROCs and ROCs predicted 
using the other measures of inter-patient variation were observed (data not shown). The 
clinical range of successful treatment coverage for standard treatment, defined as those 
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subjects whose HIV titer were undetectable after 48 weeks of treatment (Ledergerber et 
al. 1999) was approximately 90%.  
 
 
Figure 4.4. Comparison of Clinical Range of Coverage (ROC) to in silico ROC. The clinical 
(ROC), or percentage of subjects successfully responding to HAART, pertaining to 2 standard 
treatment interruption (STI) studies (Dybul et al. 2001, Fagard et al. 2003) and standard treatment 
(Ledergerber et al. 1999) was compared to in silico ROCs predicted by this study. The best 
results were observed when inter-patient variation was simulated by 25% variation in the HIV 
model parameters. The in silico ROC describing the success of optimized HAART was found be 
greater than that of 1 week on – 1 week off treatment and less than that of full and 8 weeks on  - 2 
weeks off STI. 
 
The 8w/2w STI was predicted by our study to provide a high ROC.  In the clinical 
study, subjects were required to have an undetectable viral load ([HIV] < 50 copies/mL 
for 6 months prior to study) and a CD4 count of 300,000 cells/mL in order to participate 
in the trials (Fagard et al. 2003). In the published clinical results, this strategy provided a 
77.5% ROC after 40 weeks of treatment. For this STI strategy, using a simulated inter-
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patient variation of 25% in the model parameters, the ROC predicted by the simulation 
(82.34% ± 1.22%) was very close to the ROC found clinically (77.5%).  
The 1w/1w STI strategy was predicted to provide the lowest ROC. In the clinical 
study carried out by Dybul et al (Dybul et al. 2001), ten subjects were enrolled that had 
previously responded well to continuous treatment and entered with HIV RNA levels 
below 50 copies/mL and CD4+ T-cell counts above 300,000 cells/mL. Eight of the ten 
subjects who completed this study were observed to maintain an HIV titer below 50 
copies/mL. It was also observed that small changes in adherence that increased the length 
of the STI by a few days would lead to loss of control of the HIV titer. The ROC 
calculated for the 1w/1w STI in the in silico cohorts was 46.41% ± 1.59% at a simulated 
inter-patient variation of 25% in the HIV model parameters. The estimated ROC was 
considerably lower than observed in the clinical proof-of-concept study (Dybul et al. 
2001). This result could be explained by the fact that the patients in the clinical study 
were described as those who had long-term control of plasma viremia and potentially had 
not developed drug resistance during suboptimal antiviral therapy.  As a result, these 
individuals likely represented a subset of the in silico population with more robust 
immune parameter values. 
 
 
4.4 Discussion 
Administration of standard HAART yielded the best range of successful treatment 
coverage in each cohort while 1w/1w STI yielded a smaller range of coverage as has 
been observed clinically. The 8w/2w STI treatment strategy provided a range of coverage 
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approximating that of full HAART despite administration of 16.7% less drug than the 
maximum; this finding was consistent with published clinical trial results in vivo.  
Our study then evaluated if even lower levels of drug exposure could be 
optimized in a computer-generated in silico population to retain suppression of HIV-1 
viremia. A theoretical HAART regimen was optimized to minimize total HAART 
administered for the average subject with the constraint that HIV-1 titers were to be 
reduced below detectable limits. It was predicted to successfully treat almost 70% of a 
computer-generated cohort while using a smaller amount of drug then the standard 
HAART strategy or the 8w/2w strategy. Although ROCs yielded by optimized HAART 
in the model were somewhat lower than those from maximum HAART dosage 
administered under standard therapy, lower drug exposure prescribed by optimized 
HAART implies less severe detrimental side effects. As a result, the potential exists for 
improving the quality of life for a significant number of infected individuals. The range 
of coverage results predicted by the in silico model demonstrate the ability of a systems 
biology approach to optimize HAART for a theoretical subject as well as to predict the 
effectiveness of a HAART treatment strategy for a theoretical cohort in advance of 
exposing real human subjects to the hazards of a clinical trial. For example, the model 
correctly predicted the limited ROC for most of the 1w/1w STI. The poor response to this 
STI strategy as demonstrated in the modeling confirmed the results of the clinical trials 
(Dybul et al. 2001). Thus, the approach utilized in this study has the potential to save the 
significant time and resources expended on such clinical trials and avoid patient risk. 
More importantly, such modeling could theoretically prevent patients from being put at 
unnecessary risk during testing of therapeutic strategies unlikely to be effective. The 
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relative ease and low-cost of testing novel treatment strategies with a systems biology 
approach can potentially predict clinical outcomes in a large in silico cohort without the 
time and resources required for completion of a clinical trial. As a result, the approach 
described in this study may facilitate hypothesis generation and provide preliminary 
exploratory analysis of new therapies or treatment strategies. It may furthermore assist in 
the development of more focused and precise treatment improving the likelihood of 
success and minimizing the likelihood of failure.  
Our study also shows that “one-size-fits-all” treatment strategies fail to strike an 
adequate balance between viral control and minimization of drug dosage. The standard 
HAART regimen and the 8w/2w STI regimen prescribe more HAART and yield greater 
ROCs. Even though these two treatment regimens have high ROCs, they also cause 
increased risk of the treatment-associated side effects previously described. It is thus of 
interest to develop HAART treatment strategies which balance the need to administer a 
high enough concentration of HAART to control the infection while also administering a 
small enough concentration of HAART to minimize risk of treatment-associated side 
effects. This treatment strategy is consistent with modeling directed to an optimal 
treatment strategy.  
HAART in the current study was optimized to the average subject described by a 
published model of HIV infection using an objective function calling for the 
minimization of HAART dosage while maintaining the HIV titer below 50 copies/mL. 
The same method of HAART optimization for the average subject could potentially be 
applied to derive an in silico model using an individual subject’s CD4+ T-cell counts and 
HIV-1 titers so as to optimize HAART for that individual subject. The modeling could 
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theoretically be employed using data on an individual’s immune and viral kinetics to 
optimize dosing for that particular individual. Appropriate modeling could identify those 
patients who either require more than average antiretroviral drug exposure to maintain 
virologic suppression, or those that could be safely provided lower levels of antiretroviral 
drug exposure to reduce the incidence of medication-related adverse effects while still 
maintaining durable virologic suppression. Patients identified at the extremes of 
variability in the models could be candidates for individually modified and optimized 
HAART strategies. As personalized medicine becomes more predominant, HAART 
dosing that is customized to each individual patient based on individual kinetics will 
likely be an important strategy to achieve maximal therapeutic efficacy with minimal 
exposure to drug.  
This study demonstrates the theoretic application of differing HAART strategies 
by analyzing computer-generated in silico cohorts of subjects with a systems biology 
approach. Such an approach can potentially predict greater treatment optimization and 
reduced antiretroviral drug exposures. These systems biology methods analyzing HIV-1 
treatment optimization and range of coverage prediction have significant implications for 
the evolving field of personalized medicine. Using optimization of a daily HAART 
regimen for treatment of HIV-1 in a computer-generated individual considered to be the 
average individual as a model system, it was shown that the range of successful treatment 
coverage of optimized HAART is much greater than that of most experimental STI 
regimens. As a result there is considerable potential for systems biology to play an 
integral role in optimizing the therapy of HIV-1 patients that administers the minimum 
HAART dosage while still maintaining durable viral suppression. In addition, there are 
	   67	  
implications for the emerging field of personalized medicine.  Specifically, the method 
presented for HAART optimization may be applied to the individual patient based on 
their specific physiological profile as characterized by their immune response kinetics.   
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CHAPTER 5 
DISCOVERY OF BIOCHEMICAL KINETICS AND MECHANISM USING A 
GEP-BASED EVOLUTIONARY ALGORITHM 
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5.1 Introduction 
 Mathematical models are used in nearly all industries to analyze data, make 
predictions, and propose improvements based upon those predictions. Mechanistic 
models describing chemical kinetic data sets are often defined by making assumptions as 
to some model structure. Modeling of viral systems such as HIV-1, hepatitis B, and 
others has been of great interest in the hopes of developing treatment strategies based 
upon those models (Aviran et al. 2010, Bonhoeffer et al. 1997(a,b), Burg et al. 2009, de 
Sousa and Cunha 2010, Guedj and Neumann 2010, Herz et al. 1996, Krishnan and Dixit 
2011, Nowak and May 2000, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer 
2000, Srivastava et al. 2002, von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang 
2010) . Many models of various sizes and structures have been proposed for these 
systems taking into account a wide range of biochemical species. Depending on the 
species taken into account and their predicted relationships, the model behavior can vary 
in response to any type of perturbation. The most comprehensive approach for 
determining models describing biochemical systems would be to assume no prior 
knowledge about the systems and the way that the species interact. In theory, it should be 
possible to leverage an evolutionary algorithm to infer a mechanistic model describing 
the species and their interactions, including some that may not be inherently obvious. The 
resulting model could then be used to make predictions about the system, as well as to 
test and optimize potential therapeutics. 
 Recently, work has been done on model generation from experimental data sets 
without assuming any prior knowledge about system mechanism. Schmidt et al.’s Eureqa 
formulize, a symbolic regression package that uses a genetic programming approach, 
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quickly fits models to input data (Schmidt and Lipson 2009). Although these models 
provide a good fit to experimental data, they often do not provide mechanistic 
information as to how species in a biological system interact. Chattopadhyay et al. 
developed an algorithm for inferring stochastic reaction mechanism from experimental 
data (Chattopadhyay et al. 2013). This algorithm was successful at generating correct 
mechanistic models on the algorithm’s error-complexity Pareto front, but some 
knowledge of the system was required in order to select the correct model from a set of 
potential models. A study by Bazil et al. provided a method for the reverse engineering of 
biological networks by generating systems of ordinary differential equations from 
experimental data (Bazil et al. 2011).  This algorithm was successful in identifying 
candidate pathways that were known to exist but also generated many false positive 
pathways, as the algorithm was designed to minimize the number of false negative 
pathways identified.  
A common method used in these approaches is that of genetic programming.  
Genetic programming is a type of evolutionary algorithm that generates programs or 
models of varying size and structure while not assuming any pre-defined model structure. 
The model is chosen by defining a set of functions (i.e. +, -, *, /), and a set of terminals 
(i.e. variables, real numbers) as building blocks from which to construct equations (Koza 
1992). Genetic programming works by generating a population of potential models of a 
problem where each solution consists of the defined functions and terminals. The 
potential models are ranked or scored based upon a defined fitness function. Models are 
then selected, usually in proportion to their fitness score, to undergo recombination with 
other models.  The models may also undergo mutation to further increase population 
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diversity. New models are incorporated with selected existing models, and the new 
population of models is carried on to the next iteration where the algorithm repeats itself. 
A few examples where genetic programming has been used to create models addressing 
many different problems include the evolution of natural laws (Schmidt and Lipson 2009, 
Iba 2008), computer vulnerability testing (Kayacik et al. 2011), prediction of longitudinal 
dispersion coefficients in streams (Azamathulla and Ghani 2011), protein binding sites 
(Bains et al. 2004), interpretation of microbial flow cytometric data (Davey and Davey 
2011), embedding and decoding of digital watermarks (Usman et al. 2011), synthesis of 
polymorphic combinational circuits (Gajda and Sekanina 2011), pipe break prediction 
modeling (Xu et al. 2011), estimation of daily pan evaporation (Shiri and Kisi 2011), 
software engineering predictive modeling (Afzal and Torkar 2011), modular neural 
network programming (Tsai and Lin 2011), self-reproducing machines (Zykov et al. 
2005), and steel beam load capacity prediction models (Gandomi et al. 2011).          
 Models evaluated using genetic programming are described by parse trees, as 
shown in Figure 5.1. When randomly constructing a model, a node of the parse tree can 
be chosen to be a function from the defined function set or a terminal from the defined 
terminal set. When a function is chosen, two additional nodes in this case are generated to 
be evaluated by that function. The selection of a terminal will terminate a branch of the 
parse tree. 
 The parse tree structure has led to problems associated with genetic programming. 
The problem of “bloat” refers to the expansion of parse trees to very large depths (Iba 
2008, Koza 1992). Bloat is a result of over-fitting a data set. The bloat problem has been 
addressed by defining the maximum depth that a tree can reach or by using a scoring 
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function that penalizes larger solutions. Either solution to the bloat problem comes with a 
cost. Using the maximum depth approach, a function that checks the depth of each newly 
generated solution is called during each iteration of the algorithm, thus increasing the 
computational cost of the process. When using a scoring function that penalizes larger 
solutions, smaller programs that may not account for the complexity of the system tend to 
dominate the population of models. Therefore, an optimal solution of moderate to large 
depth that potentially better captures system complexity will have a smaller chance to be 
evolved within the population of solutions. 
 Secondly, the parse tree structure leads to a highly discontinuous search space over 
which the algorithm must find for the optimal model. Using the example equation 
presented in Figure 5.1, the model as defined would asymptotically approach a steady 
state after some period of time. If the “-” node was changed to a “+” node by a point 
mutation, the model would no longer converge to a steady state.  Instead, the model 
would increase without bound, resulting in a poor fitness score and likely removal from 
the population of solutions. The result is a convergence problem because the tree with the 
“+” node is only 1 point mutation away from the optimal solution and therefore would be 
desirable to keep in the population of solutions. As larger systems are explored, this 
problem is exacerbated. Therefore, the phenotypic search space over which the algorithm 
must explore is highly discontinuous as changing one node or terminal, analogous to 
moving to a neighboring point in the search space, can yield a major change in the 
behavior and therefore the score of the solution. 
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Figure 5.1. Parse-tree solution structure for genetic programming. This one-equation system 
is represented as a mass balance describing the change in some species x over time.  Such an 
equation could be generated using a genetic programming algorithm. Each node can be selected 
to be one of a set of functions or one of a set of terminals, where each function requires two 
arguments.  	  	   Gene expression programming (GEP) has been proposed to help address these 
problems by encoding the different sizes and shapes of parse trees in linear solutions of 
fixed length (Ferreira 2006). These linear solutions are then mapped to parse trees that 
can be simulated. This approach mimics the genotype to phenotype mapping observed in 
nature. In this study, the GEP enhancement to genetic programming was tailored to the 
evolution of multi-variate systems describing reaction kinetic data to address the 
discontinuous search space observed for these types of problems. 
 Genetic programming and GEP both use three primary evolutionary operations: 
selection, recombination, and mutation.  These operators are used to evoke changes in a 
population of solutions thereby exploring a search space and converging on an optimal 
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solution. Selection has received some attention as a function that can be tailored to 
increase the efficiency and efficacy of a genetic programming algorithm (Gallagher and 
Frean 2005, Gero and Kazakov 2001, Rowe et al. 2004, White and Srivastava 2011, 
Whitley 1989). Varieties of selection operations that have been described include elite 
selection (Bautista et al. 2013, Costa and Oliveira 2003), tournament selection (Blickle 
and Lothar 1995), proportional selection (Schwefel 1993), and linear ranking selection 
(Baker 1985). Elite selection requires the copying of an elite fraction of the best scoring 
solution from one generation to the next. The rest of the next generation population of 
solutions is made up of randomly recombined and mutated solutions. Tournament and 
proportional selection bias the selection of solutions for recombination and mutation by 
their score as determined by the scoring function. Linear ranking selection biases the 
selection of solutions for recombination and mutation based upon a solutions rank within 
the population as opposed to its score. Application of the appropriate selection operation 
has the potential to increase efficiency and therefore feasibility of a GEP/genetic 
programming approach.   
 It was hypothesized that by leveraging knowledge of reaction kinetic theory, 
mechanistic mathematical models of complex biological interactions could be inferred 
using an evolutionary algorithm. To test this hypothesis, an evolutionary algorithm that 
optimized reaction kinetic models of biological systems from time series data sets was 
developed. The traditional genetic programming methodology was enhanced to evolve 
more complex reaction kinetic models describing multi-variate data sets using a GEP-
based approach. The performance of this algorithm was evaluated by its ability to 
recapitulate a generic viral dynamics model from a noisy in silico data set.  
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5.2 System and Methods 
 In this proof-of-principle study, an evolutionary algorithm was used to rediscover 
the mechanism described by a model of viral dynamics (Srivastava et al. 2002) using 
computer-generated (in silico) data describing the system. The model, shown in 
Equations 5.1 - 5.3, describes the rate of change of viral template (tem), viral genome 
(gen), and viral structural proteins (struct) over time using six parameters. Figure 5.2 
depicts a network diagram describing this system. 
 (5.1)  
 (5.2)  
 (5.3)  
 
 
d[tem]
dt = k1[gen]− k2[tem]
d[gen]
dt = k3[tem]− k2[gen]− k4[gen][struct]
d[struct]
dt = k5[tem]− k6[struct]− k4[gen][struct]
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Figure 5.2. General viral dynamics system (Srivastava et al. 2002). The published model of 
general viral dynamics accounts for three species (tem, gen, and struct) participating in six 
interactions described by six parameters (k1 è k6). Viral genome (gen) in the cytoplasm enters 
the nucleus to become viral template (tem). Tem catalytically up-regulates production of gen as 
well as structural proteins (struct). Both tem and struct can be degraded. Finally, struct can 
encapsulate gen to form new viral progeny that leave the system. 
 
In this model, k1 describes the rate by which gen enters the nucleus and becomes 
tem. The model considers two degradation interactions, the degradation of tem at a rate of 
k2 and the degradation of struct at a rate of k6. Tem catalytically up-regulates gen at a rate 
of k3 and struct at a rate of k5. Finally, the interaction occurring at a rate of k4 models the 
encapsulation of gen by struct to yield new viral progeny that leaves the system. Table 
5.1 lists the parameter values for this model (Srivastava et al. 2002). 
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Table	  5.1.	  Viral	  Dynamics	  Model	  Parameters	  Parameter	   Value	   Units	  k1	   0.025	   day-­‐1	  k2	   0.25	   day-­‐1	  k3	   1.00	   day-­‐1	  k4	   7.5*10-­‐8	   molecules-­‐1day-­‐1	  k5	   1000	   day-­‐1	  k6	   1.99	   day-­‐1	  
 
 
Genetic programming methods can represent programs or equations as trees made 
up of functions and terminals. In assembling random trees, some potential models may 
not include production or consumption terms for some of the mass balances. Potential 
models also might not include explicit parameters for some interactions (equivalent to an 
assumed reaction parameter of 1), and some terms may include tertiary and higher-order 
interactions. For the evolution of reaction kinetic models, a heuristic limiting the search 
space to models that include production and consumption terms for each species was 
applied. Each production and consumption interaction in each candidate model was also 
described by a reaction parameter. Finally, for the biological models of interest, it was 
assumed that each interaction could include one or two reactants that could catalyze or be 
consumed to generate one or two products (Levenspiel 1972). Tertiary and higher-order 
interactions were therefore eliminated from consideration. 
 To tailor a genetic programming approach to generate desired reaction kinetic 
models, the structure of candidate solutions was changed from a parse tree structure to 
the structure shown in Figure 5.3A. This representation, inspired by a GEP approach, 
encodes solutions as a “genotype,” such as a list or collection of lists, which are then 
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mapped to a “phenotype,” such as a set of parse trees shown in Figure 5.3C. Therefore, 
this evolutionary algorithm was programmed to map a list of reactants, reaction 
parameters, products, and types of reactions to parse trees describing the time series 
derivative of each variable under consideration. Such an approach resulted in a reduction 
of the size of the search space over which the evolutionary algorithm navigated to find a 
mechanistic mathematical model.  
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Figure 5.3. Mapping of model genotype to model phenotype in evolutionary algorithm. (A) 
Each potential model was encoded as an interaction table describing reactants, reaction 
parameters, and products. Each interaction was also classified as a catalytic or consumption 
interaction. This table, representing a list of reactions (B), was then translated using mass action 
kinetic theory into a system of ordinary differential equations that could be represented as a set of 
parse trees (C). These equations were then simulated and scored against an experimental data set 
(D).  
 
Another contributing factor to the large search space size the need to search for 
both the optimal model structure and optimal model parameters. Even if a good model 
structure was found, it was still unlikely that the algorithm would converge on the 
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optimal set of parameters. To address this problem, parameter estimation was carried out 
for every potential model against the experimental data during each generation of the 
evolutionary algorithm. 
   
5.3 Algorithm 
 It was observed in early versions of the algorithm that the absence of one 
necessary interaction could result in a poor scoring model that might not survive in the 
population of models (data not shown). This was yet another effect of the discontinuous 
search space associated with these types of problems. Such behavior goes against the 
assumption underlying evolutionary algorithms that optimal solutions could be built up 
gradually from suboptimal solutions containing pieces of the optimal solution. To resolve 
this issue, models were built up in a step-by-step fashion where only one equation was 
allowed to be modified at a time. 
The biochemical kinetics discovery algorithm is first described for an n-species 
system.  To generate a complete kinetic model, a mass balance for a single species was 
evolved.  Simultaneously, the mass balances for the other species were described by 
fitted polynomials during scoring. Polynomials were fit to every three consecutive data 
points and stored for use in the algorithm.  This combination of one evolved mass balance 
and n-1 polynomial fits was called an instance.  One instance was generated for each 
species such that every species had an instance in which it was represented by an evolved 
mass balance equation.  The general approach is outlined in Figure 5.4.  The best scoring 
mass balance from the collection of instances was taken as the most probable result and 
that mass balance was fixed for the next step. The species described by this result was 
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referred to as Species A. In other words, all of the remaining instances had their Species A 
polynomial fit replaced by the Species A mass balance.  During the next step, instances of 
the evolutionary algorithm were carried out to evolve a mass balance for each of the 
remaining species one at a time. The mass balance describing Species A was fixed, and 
the mass balances describing the species not being evolved were described by a set of 
polynomials. Again, the best scoring result from this set of instances was fixed for the 
next step and this variable was defined as Species B. For a system of n-species, this 
procedure would continue until only one species remained for which a mass balance had 
not yet been evolved. 
 The evolutionary algorithm was then used to evolve a mass balance describing 
this last species, while the mass balances describing the other species were fixed. This 
species was defined as Species ξ where ξ related to the number of species for which a 
time series data set existed. After this, the mass balance for Species A was re-evolved 
using the evolutionary algorithm where mass balances describing Species B through ξ 
were fixed. The existing result for Species A and the newly evolved solution were 
compared by scoring with the current set of equations describing Species B through ξ and 
the best scoring solution was kept and fixed for subsequent steps. The mass balances for 
Species B through ξ were then re-evolved one at a time in the order that they were first 
evolved. This method was carried out cyclically until the mass balances describing 
Species A through ξ remained the same over one full cycle. The information gained from 
these steps was ultimately used to seed the first generation population of a final 
evolutionary step during which mass balances describing each of the species under 
investigation were simultaneously evolved.  
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Figure 5.4. Algorithm for the discovery of a biochemical kinetic model describing an n-
variable system. Mass balances were evolved in a step-by-step manner to reduce the search 
space during a single evolutionary algorithm instance. In the initial steps, species mass balances 
were approximated by a set of polynomials fit to the corresponding data set until a mass balance 
was evolved for that variable. Once a complete model was preliminarily proposed, each species’ 
mass balance was re-evolved one at a time until the system of mass balances had not changed 
over one complete cycle. The model was finalized by carrying out one final evolutionary 
algorithm optimization during which all mass balances were simultaneously evolved. Figure 5.5 
summarizes the procedure used during each step to evolve an optimized mass balance. 
 
 Inputs for this evolutionary algorithm included the maximum number of 
allowable interactions, the population size, the species under investigation, time series 
data sets describing these species, the initial conditions used to collect the data set, any 
fixed mass balances, and the number of generations to be run before the algorithm 
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terminated. The number of interactions that potentially described a system increased 
exponentially with the number of species under investigation. Therefore the number of 
interactions allowed to describe a model was capped by the square of the number of 
species (n2) plus one in order to maintain computational tractability. n2 represented the 
number of interactions required for each species to be up-regulated by each other species, 
to be consumed to produce each species, and to be degraded. Up to one additional 
interaction was considered as binary interactions and constitutive production interactions 
were also considered. Individual mass balances considered fewer interactions when 
evolved and each species had the chance to participate in every interaction during the 
simultaneous evolution step.  
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Figure 5.5. Evolutionary algorithm for the discovery of biochemical mechanistic model. This 
flowchart details the procedure for discovering a mechanistic model for an n-species system. An 
initial population of candidate solutions was generated as encoded interaction tables. During each 
generation of the algorithm, 10,000 random parameter combinations were generated and scored 
using model calculations of species accumulation and estimates of experimental data derivatives. 
The top five scoring parameter guesses were used as initial guesses to a numerical parameter 
optimization function with the exception of single mass balance steps where parameters were not 
numerically optimized until the final step. The best scoring parameter set was then used to score 
the solution against the validation condition. An elite selection strategy was applied.  The best 
scoring solutions were copied to the next generation.  Then solutions were selected, recombined, 
and mutated to fill out and diversify the next generation’s population of solutions. This procedure 
was repeated until the termination criterion was reached. The top scoring solution in the final 
generation population was considered to be the optimized model.  
 
Populations of potential solutions were generated and scored by simulating each 
model using Mathematica on each training condition. Each potential solution in the first 
generation population of individual mass balance runs was initialized with a constitutive 
production term and a first order degradation term. The simulation results were compared 
to the training data set and scored using the corrected Aikaike Information Criterion 
(AICc) method (Aikaike 1974). Parameters were estimated for every solution every 
generation. During the simultaneous optimization step, 10,000 random parameter sets 
were generated and scores were estimated by comparing derivatives calculated using 
model mass balances to derivatives calculated using the polynomial fits to the 
experimental data set. The top five scoring parameter sets were then used as initial 
guesses for Mathematica’s numerical optimization function. The objective function was 
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minimization of the AICc score. Once optimized, each potential solution with the best 
scoring parameter set was evaluated against a validation set of data using the AICc. This 
score was associated with the potential solution during subsequent evolutionary 
operations. During individual mass balance optimization steps, numerical integration was 
not used to optimize parameters. Instead the best of the parameter sets, as determined by 
AICc, was used for evaluation of the model on the validation data. The parameters for the 
best scoring mass balances at the end of multiple trials of the evolutionary algorithm were 
optimized using Mathematica and the best result was taken as the optimized solution.   
Evolutionary algorithms utilize selection, recombination, and mutation operations 
to generate diversity in a population of solutions and facilitate convergence towards an 
optimized solution. An elite selection strategy was implemented where the top 20% of the 
best scoring solutions in the population were copied unaltered to the next generation 
population. The remaining 80% of the next generation population were made up of 
solutions randomly selected two at a time from the previous generation population that 
were given a chance to be recombined with each other and a chance to be mutated. In 
order to address potential premature convergence brought on by decreasing diversity of 
solutions in the population, the recombination rate, initiated at 90%, was decreased by 
10% every x generations, where x is equal to 10% of the number of generations required 
to terminate, until it reached 0%. Conversely, the mutation rate, initiated at 5%, was 
increased by 5% every x generations until it reached 50%. In this way, solution mutation, 
which introduces new alleles into a population thereby increasing diversity in the 
population of solutions, was the favored evolutionary operation in later generations. 
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 This algorithm is computationally intensive, and its use may be limited by the 
large amount of time it would take to run for systems of many species. To address this 
issue, the operations that could be run in parallel, such as the simulation and scoring of 
candidate solutions, and the execution of multiple instances of the algorithm, were 
parallelized. The UCONN School of Engineering’s high performance computing cluster 
consists of 768 Intel Xeon X5650 Westmere CPU cores over which parallel processes 
can be allocated. Mathematica’s built-in parallel capabilities were used to carry out this 
task.  
 
5.4 Implementation 
 The biochemical kinetics discovery algorithm was implemented to evolve the 
known mechanism of the generic viral dynamics system as a test case. An in silico data 
set was generated as the input to the algorithm. Data was generated from the published 
model using four conditions, listed in Table 5.2.  Five independent samples were taken 
every four simulated days over a period of two hundred days using 10% noise generated 
over a normal distribution. During every step of the algorithm, a population of 30 
potential solutions was evolved for up to 150 generations allowing for convergence of the 
population. During each individual mass balance optimization step, twenty-four trials of 
the evolutionary algorithm were carried out.  The best scoring solution across all trials, 
including the best result from the previous instance, was taken as the new optimized mass 
balance. Likewise, eight trials of the evolutionary algorithm were carried out during the 
final simultaneous optimization step where the best scoring result was taken as the 
	   88	  
optimized model. A maximum of four interactions were allowed to evolve during single 
species steps and a cap of ten interactions was used for the combined evolution step. 
 
Table	  5.2.	  Viral	  Dynamics	  Model	  Conditions	  For	  Data	  Generation	  Initial	  Condition	   [tem]0	   [gen]0	   [struct]0	  1	   1500	   0	   0	  2	   3000	   0	   0	  3	   5000	   0	   0	  4	   0	   1500	   0	  
 
 During the first three steps of the algorithm, a mass action kinetic equation was 
evolved first describing the change in [tem] over time, then the change in [gen] over time, 
and finally the change in [struct] over time. The interactions described by these mass 
balances are shown in Figure 5.6A. At this point in the evolution of the viral dynamics 
model, only one true pathway had been identified (the degradation of struct).  
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Figure 5.6. Evolution of the general viral dynamics model. (A) Carrying out the first three 
steps of the algorithm (Figure 5.4) resulted in a complete model describing the three species 
involved in the viral dynamics system. This proposed model consisted of eight interactions, one 
of which was consistent with the published model. (B) After additional instances of single mass 
balance optimization, the algorithm converged upon a model structure that was used to seed the 
simultaneous optimization step. (C) After the step-by-step evolution of the model was complete, 
the mass balances for all three species were simultaneously evolved. The result was two identical 
scoring models, one of which evolved to the published general model of viral dynamics. Note: 
Type “1” reactions are standard reactions, and type “0” reactions are catalytic reactions. 
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The solution shown in Figure 5.6B was used to seed the population for the last 
step during which all three mass balances were simultaneously re-evolved in order to 
determine the optimized model. The final two interactions in the seed model, shown in 
Figure 5.6B, describing the 0th-order production of tem and struct were eliminated to 
allow for more new interactions to enter the population. These two interactions were 
chosen for elimination because both tem and struct were up-regulated in other 
interactions and the constitutive production of tem and struct described by this zero-order 
reaction is very unlikely for this intracellular viral system. If these two interactions in fact 
were part of the system’s network structure, they could have re-entered the model during 
the simultaneous optimization step. After 70 generations of the simultaneous 
optimization step, the algorithm converged on two solutions of equal score (AICc = -
149.9). These solutions are shown in Figure 5.6C as Model 1 and Model 2. Model 1 
correctly predicted the degradation of tem and struct, the consumption of gen to yield 
tem, and the catalytic up-regulation of struct by tem. It incorrectly predicted that gen was 
catalytically up-regulated by struct and that gen and struct associated to yield a net of one 
struct molecule. Model 2 correctly predicted all six interactions of the generic viral 
dynamics model with no additional interactions. 
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Figure 5.7. Simulation of evolved viral dynamics models. (A) Simulation of Models 1 and 2 
against in silico data sets generated for the three training conditions (columns 1-3) and the 
validation condition (column 4) are shown. Both Models 1 and 2 had an AICc score of -149.9 
when scored against the validation condition. (B) Models 1 and 2 were tested by comparing 
simulation results to in silico data sets generated for four additional test conditions. Models 1 and 
2 had nearly identical results on the first three test conditions (columns 1-3) but Model 2 
significantly out-performed Model 1 on the fourth test condition (column 4). 
 
The performance of Models’ 1 and 2 on the training conditions (columns 1-3) and 
validation condition (column 4) are shown in Figure 5.7A. As expected by the identical 
AICc score, both models were observed to accurately fit the in silico data set. To 
differentiate between the two models, an in silico data set was generated by the same 
procedure for four new conditions, listed in Table 5.3.  
 
Table	  5.3.	  Viral	  Dynamics	  Model	  Test	  Conditions	  Initial	  Condition	   [tem]0	   [gen]0	   [struct]0	  1	   10000	   0	   0	  2	   0	   5000	   0	  3	   500	   5000	   1000	  4	   0	   0	   1000	  
 
Models 1 and 2 were simulated using each of the four new test cases, as shown in 
Figure 5.7B, and scored against the in silico data sets. Both models yielded nearly 
identical results on the first three test cases. However, models 1 and 2 showed 
significantly different results when simulated against the fourth test case. Model 1 scored 
poorly, based on its AICc value, as the struct molecules existing at t = 0 led to the up-
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regulation of gen and by extension tem. Model 2 had a better AICc score and accurately 
predicted that the initial struct molecules would not up-regulate gen or tem and would be 
degraded out of the system.  Model 2 was therefore correctly selected as the optimized 
mechanistic model for the general viral dynamics system. Table 5.4 compares the true 
model to the evolved model and its parameters. 
 
Table 5.4. Comparison of Known Equations to Generated Equations 
Known Equations Generated Equations ![!"#]!" = 0.025 𝑔𝑒𝑛 − 0.25[𝑡𝑒𝑚]	  	   ![!"#]!" = 0.025 𝑔𝑒𝑛 − 0.25[𝑡𝑒𝑚]	  	  ![!"#]!" = 𝑡𝑒𝑚 − 0.025 𝑔𝑒𝑛 − 7.5 ∗10!![𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	  	   ![!"#]!" = 0.99 𝑡𝑒𝑚 − 0.025 𝑔𝑒𝑛 −7.46 ∗ 10!![𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	  	  ![!"#$%"]!" = 1000 𝑡𝑒𝑚 − 1.99[𝑠𝑡𝑟𝑢𝑐𝑡]−7.5 ∗ 10!![𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	  	   ![!"#$%"]!" = 2570.4 𝑡𝑒𝑚 − 5.14[𝑠𝑡𝑟𝑢𝑐𝑡]−7.46 ∗ 10!![𝑔𝑒𝑛][𝑠𝑡𝑟𝑢𝑐𝑡]	  	  
 
 
5.5 Discussion 
In this proof of principal study, an algorithm for determining the mechanistic 
reaction kinetic network and associated kinetic parameters of a nonlinear system using 
time series data was developed.  The algorithm was validated by its ability to recapitulate 
a generic nonlinear viral dynamics model. To overcome issues of intractability, reaction 
kinetic theory was used to reduce the model search space by encoding models as 
interactions with reactants, parameters, and products where reactions could be classified 
as either describing consumption reactions or catalytic reactions. Convergence of the 
algorithm was also facilitated by seeding biochemical species mass balances with a 
production and consumption term as informed from domain specific knowledge. The 
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algorithm did not require any prior knowledge of the relationship among measured 
species.  
Eight total instances of model evolution were required to generate a mechanistic 
model of the viral dynamics system. The model went through two major intermediate 
steps before arriving at two final models that fit the validation condition equally well. 
Four scenarios using different initial conditions were used to differentiate between the 
two models and one was selected as the optimized mechanistic model. The parameters 
estimated with the evolved model were 160% of the parameters from the published 
model used to generate the in silico data set, and in most cases were almost identical. 
This means that the algorithm converged upon a sub-optimal parameter set for this 
model. 
Interactions between large numbers of species are commonly found in biological 
systems; therefore it is important that a biochemical kinetics discovery algorithm be able 
to analyze systems of many species. The enhancements to the traditional genetic 
programming algorithm used in this study have the potential to carry out such an 
analysis. The maximum number of interactions suggested is the square of the number of 
species plus one, but it is possible to specify a reasonable number of interactions specific 
to the system under investigation that goes beyond this value if deemed appropriate.  It is 
expected that running this algorithm for systems where a greater number of species are 
being considered will take longer to converge on a mechanistic mathematical model. 
Because of this, the published Mathematica code is designed to be monitored and 
terminated when a potential solution has not improved during a sufficient number 
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generations. The algorithm therefore has the potential to be beneficial in generation 
models of complex biological systems. 
Future research into the performance of this algorithm may identify ways to 
improve its computational efficiency and by extension its ability to converge to an 
optimal solution in a timely manner. One such approach may be to change the way by 
which parameters for potential solutions are trained and validated. In this study, data 
simulated using three different scenarios were used to infer solutions and a fourth was 
used to validate solutions by assigning a score using AICc. This score was then used to 
carry out evolutionary operations. Depending on the data set collected, it may be 
necessary or preferable to assign a portion of a data to the training data set and another 
portion to the validation data set, a common practice in the field of machine learning.  
Similarly, when multiple candidate solutions emerge, as was the case in this study, there 
is the potential to embed testing conditions into the algorithm. For example, a data set 
describing the responses of the variables of interest to a perturbation could be recorded 
and fed to the algorithm for this purpose. Also, another method of comparing the 
candidate solutions, such as the F-test, could be utilized. These approaches would replace 
the ad hoc testing done in this study.  
Another such avenue for potential improvement will be regarding how 
interactions are chosen to be involved in a potential solution. Depending on the likelihood 
of an interaction being present in the system, a bias may be introduced that would make 
particular interactions more or less likely to be present in a potential solution. For 
example, a bias against dimerization interactions could be introduced when analyzing a 
system such as the one in this study where such interactions are unlikely to occur. Such 
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an improvement may prove critical in facilitating convergence of larger systems to an 
optimized solution. 
In conclusion, mechanistic models describing biological systems have the 
potential to guide the discovery of drug targets and therapeutic strategies.  This study 
demonstrates a method of generating mechanistic mathematical models describing 
biological systems from experimental data sets. This technology has the potential to be 
useful in a variety of areas ranging from biomedical to biotechnological.  For example, 
for personalized medicine applications, the tailoring of mathematical models to an 
individual’s disease state based upon their unique biochemical kinetic markers could 
allow clinicians to make predictions about an individual’s disease state and optimize their 
treatment.  Biotechnologically, through the inference of bioprocesses, advances in the 
discovery of pathways associated with microbial fuel production, for example, could lead 
to novel insights into the optimization of these processes. Further, this algorithm has the 
potential to be useful in any application where the relationship between biochemical 
species is at question. 
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CHAPTER 6 
INFERENCE OF COHORT-SPECIFIC HIV-1 KINETICS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   98	  
6.1 Introduction 
Human immunodeficiency virus type 1 (HIV-1) is an important disease that has 
received significant interest from the modeling community (Aviran et al. 2010, 
Bonhoeffer et al. 1997(a,b), Burg et al. 2009, Herz et al. 1996, Nowak and May 2000, 
Perelson et al. 1996, Perelson 2002, Prosperi et al. 2009, Ribeiro and Bonhoeffer 2000, 
von Kleist et al. 2010, Wu and Zhang 2010, Zeng and Yang 2010). In recent years, HIV-
1 treatments have significantly reduced AIDS-related mortalities and have enhanced 
long-term disease control (Dybul et al. 2001, Fagard et al. 2003, Powderly 2002, Ruiz et 
al. 2001).  These benefits have been realized in large part via use of highly active 
antiretroviral therapy (HAART) in clinical practice.  The HAART strategy consists of 
treating the disease with a combination of antiretroviral drugs.  Despite advances in 
efficacy over prior generation treatments, HAART is associated with risk of serious side 
effects that include cardiovascular disease (Domingos et al. 2009), nephrotoxic effects 
(Izzedine et al. 2009), and oral toxicities (Nittayananta et al. 2010). Up to 16% of 
patients require modification or discontinuation of their HAART regimen due to drug-
related toxicities (Mocroft et al. 2005). 
A major goal of developing mathematical models of diseases such as HIV-1 is to 
understand the underlying pathology and to predict progression of the disease (Bogojeska 
et al. 2010, Burg et al. 2009, Castiglione and Paci 2010, de Sousa and Cunha 2010, 
Degon et al. 2008, Guedj and Neumann 2010, Hoffmann et al. 2002, Itakura et al. 2010, 
Perelson et al. 1996, Smith and Ribeiro 2010, Srivastava et al. 2002, von Kleist et al. 
2010, Wendelsdorf et al. 2010). One of the benefits arising from such a quantitative 
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understanding is the potential to develop and optimize treatment strategies that maximize 
health benefits while minimizing secondary toxicity effects.   
 Mathematical models of biochemical systems, such as HIV-1 pathogenesis, are 
often defined by making assumptions as to the important reactions that consume and 
produce the variables of interest. Reaction kinetic theory is then applied to formulate 
mathematical models of these systems where reaction parameters are optimized using 
experimental data sets. Therefore, many models of various sizes and structures have been 
proposed for such systems taking into account a wide range of variables. Depending on 
the variables taken into account and their predicted relationships, a system’s model 
behavior can vary in response to perturbation.  
 A more robust approach to determine a mathematical model describing a 
biochemical system, such as HIV-1 pathogenesis, would be to assume no prior 
knowledge about the system and the way that the variables of interest interact. Therefore, 
it would be useful to leverage an evolutionary algorithm (Blickle and Lothar 1995, 
Chattopadhyay et al. 2013, Costa and Oliveira, Iba 2008, Koza 1992, Schmidt and Lispon 
2009) to derive a reaction kinetic model describing the variables of interest, taking into 
account all necessary variable interactions including some that may not be inherently 
obvious. The resulting model could then be used to make predictions about the system as 
well as to test and optimize potential therapeutics. 
 In this study, an evolutionary algorithmic approach was utilized to generate reaction 
kinetic models from clinical data describing HIV-1 infection in three cohorts of HIV-1 
positive subjects receiving three different HAART regimens. These cohort-specific 
models allowed for the analysis of HIV-1 pathogenesis in each cohort as active 
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biochemical pathways existing between CD4+ T-cells and HIV-1 were hypothesized. The 
inferred pathways were used to evaluate HAART effectiveness in each cohort as well as 
to makes predictions about the potential for viral rebound. Significantly, this study 
demonstrates a method by which reaction kinetics models describing HIV-1 pathogenesis 
can be inferred directly from clinical data.  
 
6.2 Methods 
6.2.1 Selection of Subject Data 
CD4+ T-cell and HIV-1 data describing eight HIV-1 positive male subjects was 
taken from Zhang et al. (Zhang et al. 1999). Subjects 1, 2, and 5 (Cohort 1) received 600 
mg/day Zidovudine, 300 mg/day Lamivudine, and 1200 mg/day Ritonavir, subjects 3, 4, 
and 6 (Cohort 2) received 600 mg/day Zidovudine, 300 mg/day Lamivudine, and 2400 
mg/day Indinavir, and subjects 7 and 8 (Cohort 3) received 600 mg/day Zidovudine, 300 
mg/day Lamivudine, 1200 mg/day Ritonavir, and 1200 mg/day Saquinavir. Since plasma 
viremia was not detected after the 5th month of treatment, only data from time = 0 to 
approximately the 5th month of treatment was considered for analysis. This data is 
depicted in Figure 6.1. 
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Figure 6.1. [CD4+] and [HIV-1] Data Describing HIV-1 Positive Subject Cohorts. CD4+ T-
cell and HIV-1 concentration data from eight HIV-1 positive subjects was obtained from (Zhang 
et al. 1999). Only the first five months of data were considered as this was the only period in 
(Zhang et al. 1999) during which significant changes in [CD4+] and [HIV-1] were observed. The 
subjects were re-organized into three cohorts, Cohort 1 (Subjects 1, 2, and 5), Cohort 2 (Subjects 
3, 4, and 6), and Cohort 3 (Subjects 7 and 8), where the subjects making up each cohort each 
received the same treatment regimen. 	  
6.2.2 Optimization of Models Using an Evolutionary Algorithm 
 Reaction kinetic models of ordinary differential equations describing the change 
in both [CD4+] and [HIV-1] over time were evolved using the algorithm depicted in 
Figure 6.2. This algorithm is described in depth in Chapter 5. Data sets for Cohorts 1, 2, 
and 3 were used as input to evaluations of the algorithm that resulted in a model specific 
for that cohort. Model optimization steps (shown in blue and magenta in Figure 6.2) were 
carried out using an evolutionary algorithm with evolutionary parameters defined as 
follows; the population size was set to 30 models and a maximum of 150 iterations was  
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Figure 6.2. An Evolutionary Algorithmic Approach for the Optimization of Cohort-Specific 
HIV-1 Infection Models. Data sets describing cohorts of HIV-1 positive subjects were used as 
the input to an evolutionary algorithmic approach designed to output a reaction kinetic model 
describing a given cohort. First, mass balances were optimized using an evolutionary algorithm 
for both CD4+ T-cells and HIV-1 individually. The best scoring mass balance, using AICc, was 
fixed and the mass balance for the other variable, either CD4+ or HIV-1, was re-optimized. This 
mass balance was then fixed and the mass-balance for the other variable was again optimized. 
This cyclical behavior continued until both mass balances did not change over two steps. The 
entire model consisting of both CD4+ and HIV-1 mass balances was simultaneously optimized 
using an evolutionary algorithm with the result being the optimized reaction kinetic model. 
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allowed. The recombination rate was reduced by 10% every 15 iterations, starting at 90% 
and ending at 0%. Conversely, the mutation rate was increased by 5% every 15 iterations, 
starting at 5% and ending at 50%.	  
Candidate models were represented as a table of reactions, shown in Figure 6.3. A 
reaction was defined by a set of reactants, a reaction parameter, and a set of products. The 
set of reactants and products in each reaction was randomly chosen from the set {CD4+, 
HIV-1, CD4+ + CD4+, HIV-1 + HIV-1, CD4+ + HIV-1, Null} and was randomly 
designated as a catalytic reaction (parameter type = 0) where the reactants are not 
consumed in the production of the product or as a reactant consuming reaction (parameter 
type = 1). Single equation optimization steps were capped at four terms per equation and 
up to five terms were allowed to make up the final model determined in the final 
simultaneous optimization step. 
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Figure 6.3. Representation of Potential Models in Evolutionary Algorithmic Approach. 
During the generation of cohort-specific reaction kinetic models, evolutionary algorithms were 
used to build up the final model in a step-by-step fashion. These evolutionary algorithms used a 
population of potential models from which better scoring models emerged over several iterations. 
Potential models were generated as tables of reactions, where each reaction was made up of 
reactants, a reaction parameter (either describing a consumption or catalytic reaction), and 
products. Using mass action kinetic theory, a table of reactions representing a potential model 
was translated into a set of ordinary differential equations that could be simulated and scored 
against a data set (not shown). The table of reactions from an optimized model was then 
translated into a network diagram from which hypothesized reactions involving CD4+ T-cells and 
HIV-1 could be visualized.  	  
The reaction parameters describing each candidate model were optimized and 
each model was assigned a score using the Akaike Information Criterion with correction 
method (Aikaike 1974), where models that best fit the data received the lowest scores. 
Using an elite selection strategy, the top 20% of a scored population of models was 
copied unaltered to the next iteration’s population and the remaining 80% of that 
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population was comprised of randomly selected solutions that were given a chance to 
recombine and mutate to generate new and potentially better models. Eight instances of 
each optimization step were run and the best-scoring model from among the final 
populations of all eight instances was taken as the optimized solution. 
 
6.2.3 Evolution of Cohort-Specific Models 
During the first model optimization step of the algorithm, a mass balance was 
optimized for both [CD4+] and [HIV-1] in separate runs where the mass balance for the 
variable not under consideration was approximated by a polynomial fit to each series of 
three data points. This approximation was necessary to numerically integrate the mass 
balance of interest and to score it against the clinical data set. At the conclusion of this 
step, the mass balance with the best score was fixed and the mass balance describing the 
other variable was optimized again. During this step and in subsequent steps, the fixed 
mass balance was used during the numerical integration of the model for scoring 
purposes in lieu of the polynomial approximations. 
The cycle of optimizing a single mass balance describing either [CD4+] or [HIV-
1] while the previously optimized mass balance describing the other variable was fixed 
continued until there was no change in either the [CD4+] or [HIV-1] mass balance during 
the previous two steps. The model represented by these two mass balances was then used 
to seed the initial population of a final model optimization step where both mass balances 
were evolved simultaneously. The result of this step was an optimized reaction kinetic 
model describing reactions between CD4+ and HIV-1 specific to the cohort under 
investigation. 
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6.3 Results 
 Using the evolutionary algorithmic approach, reaction kinetic models describing 
the change in CD4+ T-cell and HIV-1 concentration over time were evolved for three 
cohorts of HIV-1 positive subjects. Data describing these cohorts was taken from Zhang 
et al. (Zhang et al. 1999). Cohort 1 (three subjects) received 600 mg/day Zidovudine, 300 
mg/day Lamivudine, and 1200 mg/day Ritonavir, Cohort 2 (three subjects) received 600 
mg/day Zidovudine, 300 mg/day Lamivudine, and 2400 mg/day Indinavir, and Cohort 3 
(two subjects) received 600 mg/day Zidovudine, 300 mg/day Lamivudine, 1200 mg/day 
Ritonavir, and 1200 mg/day Saquinavir. CD4+ T-cell data included both uninfected and 
HIV-1 infected cells. 
 Figure 6.4 shows the table of reactions and corresponding network diagrams 
describing each cohort’s evolved model. Cohort 1’s kinetic model hypothesized that both 
CD4+ T-cells and HIV-1 catalytically up-regulate production of HIV-1. Further, in one 
pathway CD4+ T-cells and HIV-1 are consumed to yield CD4+ T-cells and in another 
pathway they catalytically up-regulate CD4+ T-cell production. These pathways suggest 
an active infection, as presumably HIV-1 infected CD4+ T-cells catalytically produce 
new HIV-1, consistent with how HIV-1 is replicated. Similarly, the catalytic production 
of HIV-1 by HIV-1 pathway represents infection of uninfected CD4+ T-cells, whose 
concentration is approximately constant and factored into the reaction parameter, and 
replication within these newly infected cells. Finally, the second order pathway 
describing catalytic up-regulation of CD4+ T-cells by CD4+ T-cells and HIV-1 most 
likely represents an infection pathway, as the concentration of HIV-1 is not being 
reduced. Evidence of active treatment is shown in the second order pathway describing 
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production of CD4+ T-cells by the consumption CD4+ T-cells and HIV-1. In this reaction, 
HIV-1 enters the T-cell but due to the reverse transcriptase inhibitor cannot effectively 
replicate or due to the protease inhibitor yield non-infectious HIV-1. 
 
	  
Figure 6.4. Evolved Cohort-Specific Reaction Kinetic Models. Reaction kinetic models 
involving CD4+ T-cells and HIV-1 were evolved for Cohorts 1 (A), 2 (B), and 3 (C) using an 
evolutionary algorithmic approach. In the evolutionary algorithmic approach, models were 
represented as tables of reactions, where each reaction was made up of reactants, a reaction 
parameter (either describing a consumption or catalytic reaction), and products. The table of 
reactions was then used to generate a network diagram describing the mechanism hypothesized 
by each model.  	  	   Cohort 2’s kinetic model hypothesized that CD4+ T-cells are constitutively 
produced in one pathway and are eliminated in another pathway. In a third pathway, 
CD4+ T-cells and HIV-1 are eliminated together. This system of reactions suggested that 
treatment was effective. For example, constitutive production of CD4+ T-cells as well as 
their elimination are pathways expected in a healthy subject. Further, the second order 
interaction of CD4+ T-cells and HIV-1 elimination suggests that infected CD4+ T-cells 
are detected and eliminated by the immune system.   
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 Cohort 3’s kinetic model hypothesized that CD4+ T-cells are eliminated in a 
second order reaction. Also, CD4+ T-cells and HIV-1 are consumed to yield CD4+ T-
cells. These pathways also suggest effective treatment as elimination of uninfected CD4+ 
T-cells is expected in healthy individuals and elimination of HIV-1 infected CD4+ T-cells 
is beneficial in clearing the infection. Further, as seen in Cohort 1, production of CD4+ T-
cells by the consumption CD4+ T-cells and HIV-1 suggests that HIV-1 entering the T-cell 
does not effectively replicate due to the action of reverse transcriptase and protease 
inhibitors.  	  
Table 6.1. Cohort-Specific Model Reaction Parameters 
Cohort 1 Cohort 2 Cohort 3 
k1 7.47*10-6 1/(H*t) k1 69.22 C/t k1 0.018 1/(C*t) 
k2 7.35 H/(C*t) k2 1.58*10-8 1/t k2 0.045 1/(C*t) 
k3 158.06 1/t k3* 2.21*10-5/ 
3.36*10-2 
1/(H*t)    
k4 0.26 1/(C*t) 
C = cells/mm3; H = copies HIV-1/mL; t = months 
* The reaction parameter was evolved to be 2.21*10-5 in the CD4+ mass balance and 
3.36*10-2 in the HIV-1 mass balance. 	  	   	  	   The parameters evolved for each cohort’s reaction kinetic model are shown in 
Table 6.1. Figure 6.5 shows the results of simulating these models with the evolved 
parameters and plotting the results with each cohort’s data set. Models for Cohort 1 and 
Cohort 2, AICc = 93.54 and AICc = 115.56 respectively, show good agreement with the 
HIV-1 data set. HIV-1 concentration fell to undetectable limits in both Cohort 1 and 
Cohort 2, consistent with the models, which hypothesized active treatment pathways. 
Cohort 1’s model showed adequate agreement with the CD4+ T-cell data set but Cohort 
2’s model did not show a strong correlation. CD4+ T-cell concentration is predicted to 
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plateau in Cohort 1 where as in Cohort 2 the CD4+ T-cell concentration is predicted to 
climb over the five-month time frame. This is most likely due to the active infection 
pathways hypothesized for Cohort 1.  
 
	  
Figure 6.5. Cohort Model Simulations and Comparison To Clinical Data. Evolved models for 
Cohort 1 (Subjects 1, 2, and 5), Cohort 2 (Subjects 3, 4, and 6), and Cohort 3 (Subjects 7 and 8) 
were simulated and plotted with the clinical data set obtained from (Zhang et al. 1999). Models 
for Cohorts 1 (AICc = 93.54), Cohort 2 (AICc = 115.56), and Cohort 3 (AICc = 130.80) showed 
good agreement with the clinical HIV-1 data set. Cohort 1’s model showed adequate agreement 
with the clinical CD4+ T-cell data but Cohort 2’s and 3’s model did not show a strong correlation. 	  	   Cohort 3’s model, AICc = 130.80, showed good agreement with HIV-1 
concentration data but did not closely predict CD4+ T-cell concentration data due to the 
lack of a CD4+ T-cell production pathway in the model. Even though a CD4+ T-cell 
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production pathway should exist for this cohort, the evolved model determined the CD4+ 
T-cell and HIV-1 clearance pathways as most important and was therefore successful in 
describing the down-regulation of HIV-1 in this cohort. 
 
6.4 Discussion 
 This work significantly demonstrates a method by which interactions involving 
CD4+ T-cells and HIV-1 can be inferred from HIV-1 positive subject cohort data. The 
hypothesized interactions can be used to assess the effectiveness of a drug cocktail on a 
cohort of subjects as well as to make predictions regarding viral rebound. In this study, an 
evolutionary algorithmic approach was successfully able to hypothesize pathways for 
three cohorts receiving different drug cocktails that showed the action of reverse 
transcriptase and protease inhibitors in down-regulating HIV-1 infection. It was also 
hypothesized that HIV-1 replication continued in Cohort 1. This result suggests that viral 
rebound and potentially mutation may emerge if treatment was to be continued. 
Interestingly, Zhang et al. found that viral replication did continue in Subject 5, a 
member of Cohort 1, in the months after the period of early infection used for this study 
(Zhang et al. 1999). Drug resistant HIV-1 strains were also found in this patient. 
 In addition to evolving reaction kinetic models for these three cohorts, models 
were evolved for each individual subject using their specific [CD4+] and [HIV-1] data 
(data not shown). Further, a reaction kinetic model was evolved to describe the cohort of 
all eight subjects used in the Zhang et al. study by pooling their [CD4+] and [HIV-1] data 
together (data not shown). It was found that models evolved for the individual subjects 
did not describe mechanism that one would expect to exist between [CD4+] and [HIV-1] 
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but rather merely provided a means by which the data could be fit. These results were due 
to the limited amount of data available for each patient during the early infection period. 
Likewise, the model evolved using data pooled from all eight subjects also did not 
describe mechanism that one would expect to exist between [CD4+] and [HIV-1]. This 
result was due to a loss in data resolution, as the subjects under investigation received 
different treatment regimens. Therefore, the cohort models were selected for analysis. 
 It is anticipated that this evolutionary algorithmic method will be used to discover 
biochemical mechanism in HIV-1 positive cohorts as well as in patient’s suffering from 
other like diseases. The key to success of this method is the availability of relevant data; 
large cohorts for whom large amounts of data exist will result in meaningful results. 
Additionally, this method has the potential to be applied to data taken from a single 
subject for which a large amount of dynamic data exists. The evolved model could then 
be used to predict the disease course for this individual and to optimize a personal 
treatment plan.   
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CHAPTER 7 
CONCLUSIONS AND FUTURE DIRECTIONS 
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7.1 Conclusions 
 In conclusion, a GEP-based evolutionary algorithm was developed for the 
evolution of mass action kinetic models describing systems of biochemical species from 
time series data sets. These models are not built up assuming prior knowledge of how the 
variables of interest interact but significantly infer the system’s reaction kinetics from the 
data set. Therefore, this algorithm should be utilized as a hypothesis-generating tool 
where pathways inferred using the evolutionary algorithm and previously not known to 
be important in the system can be experimentally verified.  
 It was also shown that by applying the GEP-based evolutionary algorithm cohort-
specific interactions between CD4+ T-cells and HIV-1 could be elucidated. These 
interactions were used to determine the effectiveness of the HAART regimen prescribed 
for each cohort and to make predictions about potential HIV-1 rebound. In a clinical 
setting, the evolved models could be used to simulate the effectiveness of a HAART 
regimen or to optimize a HAART regimen for that cohort as was done in Chapter 5.    
 It is anticipated that this methodology will be applied to reaction kinetic models 
describing a variety of biochemical phenomena. Importantly, when applied to modeling 
disease states, the GEP-based evolutionary algorithm has the potential to be applied to 
evolve a model describing a subject’s unique set of biochemical markers. The model 
could then be utilized to optimize a treatment strategy specific to that subject that would 
most effectively treat the pathways associated with that individual’s disease state.  
 Application of the GEP-based evolutionary algorithm is not restricted to 
biochemical problems but could also be useful in discovering patterns underlying any 
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time series data set. Evolved models would become very useful as a first step in making 
predictions about interactions between variables as well as in simulating the system.  
 
7.2 Future Directions 
 This work opens up multiple avenues for future research. Currently, the GEP-
based evolutionary algorithm assumes that all potential interactions have the same 
probability of being part of the optimized reaction kinetic model. In some systems of 
interest, for example in the evolution of the general viral dynamics model or in the 
evolution of the HIV dynamics model, it is known that some interactions, such as 
dimerization of biochemical species, are not likely to occur. Therefore, the GEP-based 
evolutionary algorithm could be altered to include biases that would result in an increased 
probability that a sub-population of interactions enter a candidate model and a lower 
probability that another sub-population of less likely interactions are chosen to be part of 
a candidate model. 
 Further, candidate models in the GEP-based evolutionary algorithmic approach 
were trained (the model’s parameters were optimized) on a portion of the data set and 
then scored by validating each model with its optimized parameters on another portion of 
the data set. In the general viral dynamics study, see Chapter 5, where data was available 
from multiple experiments across multiple initial conditions, data from three of the four 
initial conditions was used as the model training data set and data from the fourth initial 
condition was used as the model validation data set. The training and validation of 
solutions in this algorithm is an area that deserves further scrutiny as more optimal ways 
of dividing an experimental data into training and validation data sets may yield better 
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convergence on optimal solutions has the potential to greatly decrease the computational 
intensity involved in executing this algorithm.  
 Finally, most of the GEP-based evolutionary algorithm’s evaluation time is spent 
on optimizing sets of parameters for candidate models. This step is crucial in reducing the 
solution space, as sub-optimal parameter sets are not considered. Currently, 
Mathematica’s NMinimize function is used to carry out parameter optimization. 
Implementation of more efficient and computationally less intense methods to carry out 
parameter optimization may result in increased performance of the algorithm and the 
potential for the algorithm to be applied to systems with a large number of variables.   	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9.1 Appendix 1: Elite Variant Selection Strategy Code 
The following code was written in Common Lisp. 
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9.2 Appendix 2: In silico HIV-1 Positive Subject Population Analysis Code  
The following code was written in Common Lisp. 
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9.3 Appendix 3: Biochemical Kinetics Inference Algorithm Code 
9.3.1 Instructions  
 The code contained in this package is intended to be used for the generation of 
mass action kinetic models from time series biological data sets. The four programs 
included in the MathematicaCode folder are as follows: 
1) EvolutaionaryAlgorithm_SingleVariableStep 
2) EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances 
3) EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround 
4) EvolutaionaryAlgorithm_CompleteModelOptimization(FinalStep) 
 The programs are intended to be used iteratively. First, the 
EvolutaionaryAlgorithm_SingleVariableStep program is to be used to evolve mass 
balances describing each variable of interest separately. This means that for a 3-variable 
system you would use 3 different versions of this code (changing it for each variable by 
following the directions included with the program). It is recommended that multiple 
instances if each program be run to validate results.  
 When multiple instances are run, the  
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances program is 
used to identify the result that should be used to describe a variable's mass balance going 
forward. THE VARIABLE FOR WHICH A MASS BALANCE IS BEING EVOLVED 
MUST BE DEFINED AT THE HEAD OF EACH VARIABLE LIST AND BE 
CONSIDERED TO BE VARIABLE 1 WHEN LISTING DATA. A numerical parameter 
optimization function is included in this program; if the program fails to terminate in a 
reasonable amount of time the parameter optimization package may be failing to 
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converge. In this case, the 
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkArou
nd program can be used to leverage the output from the 
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances program to 
find the best result. 
 Once all mass balances have been found, fix the mass balance for the variable that 
resulted in the best (lowest) score and re-run the 
EvolutaionaryAlgorithm_SingleVariableStep program for the remaining variables while 
also defining the mass balance for the fixed variable within the code. Again, for multiple 
instances use 
EvolutaionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances/Evolutaion
aryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround 
programs to identify the best solution.  
 After mass balances have been fixed for all but one variable, run 
EvolutaionaryAlgorithm_SingleVariableStep/EvolutaionaryAlgorithm_SingleVariableSte
pComparisonOfMultipleInstances programs to find a solution. Begin the iteratively re-
evolve variable mass balances in this manner beginning with the variable for which a 
mass balance was defined first. Iterate until the mass balances for each variable have not 
changed over one complete cycle. 
 Mass balances should now be proposed for each variable under investigation. Use 
the EvolutaionaryAlgorithm_CompleteModelOptimization(FinalStep) to carry out one 
final simultaneous evolution step. The result of this program will be a mass action kinetic 
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model. Again, it is suggested that multiple instances of this program be run. The result 
with the best (lowest) score will be the optimized mass action kinetic model. 
 
The following code was written in Mathematica. 
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9.3.2 EvolutionaryAlgorithm_SingleVariableStep.nb 
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9.3.3 EvolutionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstances.nb 
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9.3.4 EvolutionaryAlgorithm_SingleVariableStepComparisonOfMultipleInstancesWorkAround.nb 
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9.3.5 EvolutionaryAlgorithm_CompleteModelOptimization(FinalStep).nb 
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